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The immune system has evolved to protect organisms against invasion by foreign
pathogens. In vertebrates immune responses are mediated by cells of the innate immune
system, such as macrophages, neutrophils and dendritic cells, and by B and T cells of
the adaptive immune response. Cells react to changes in their environment by
production of new proteins. Changes, such as appearance of pathogens are detected at
the cell membrane by specific receptors, whereas the mRNA needed for de novo
synthesis of proteins is generated in the nucleus. Information therefore has to be
transmitted from the cell membrane to the nucleus, in a process called signal
transduction. Typical signal transduction pathways are initiated through cross-linking
of receptors located in the cell membrane. This leads to recruitment and modification of
intermediate “messengers”, mostly proteins and lipids, which transmit the signal from
the receptor ultimately to transcription factors. Activated transcription factors in turn
initiate transcription from promoters of their target genes, which leads to the production
of new proteins to combat the pathogen.
1.1 The NF- B Transcription Factor Family
The transcription factor family NF-kB regulates the expression of genes controlling cell
survival and proliferation, immune and stress responses, and inflammatory reactions
(reviewed in (Baldwin, 1996; Ghosh and Karin, 2002; Ghosh et al., 1998; Li and
Verma, 2002; Silverman and Maniatis, 2001)). In mammals the NF-kB protein family
contains five different Rel proteins: p65/RelA, c-Rel/Rel, RelB, p50/NF-kB1 and
p52/NF-kB2; the latter two are generated through proteolytic processing of their
respective precursor molecules p105 (p50) and p100 (p52). Rel proteins form various
hetero- or homodimeric complexes, which in most resting cells are kept inactive
sequestered to the ankyrin repeats of inhibitory molecules termed IkBs (Ghosh et al.,
1998) (Figure 1). The precursors of NF-kB1 and NF-kB2 also contain ankyrin repeats
and therefore can act as inhibitors of Rel proteins (Solan et al., 2002). Upon exposure
to a wide variety of stimuli including proinflammatory cytokines (such as TNF and IL-
1), bacterial lipopolysaccharide (LPS) and viral infection, IkB proteins are
phosphorylated on two conserved serine residues. This triggers subsequent
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ubiquitination and proteasomal degradation of the I k Bs (reviewed in (Karin and Ben-
Neriah, 2000; Verma et al., 1995)). Degradation of Ik B releases NF-k B dimers, which
then accumulate in the nucleus where they activate transcription of NF- k B target genes,
including genes encoding proinflammatory cytokines and chemokines, cell-adhesion
molecules and anti-apoptotic proteins (Karin and Ben-Neriah, 2000) (Figure 1). Recent
studies show, however, that after liberation from Ik B NF- k B/Rel proteins have to
undergo several modifications such as phosphorylation and acetylation in order to
activate transcription (Ghosh and Karin, 2002). Deficiency for the enzyme glycogen-
synthase 3 b  (GSK-3 b ) in mice leads to a defect in NF-k B-dependent gene transcription
despite normal induction of NF- k B DNA-binding (Hoeflich et al., 2000).  It seems
therefore that NF-k B activation is regulated by GSK-3b  at the level of the
transcriptional complex, most likely through the phosphorylation of RelA (Schwabe
and Brenner, 2002). Other kinases, such as PI3-K (Sizemore et al., 1999), TBK (T2K)
(Bonnard et al., 2000), z PKC (Leitges et al., 2001) and PKA (Zhong et al., 1998) have
also been implicated in the transactivation of Rel subunits by phosphorylation (Figure
1).
1.2 The I B Kinase Complex
Induced phosphorylation of Ik B is mediated by the I k B-kinase (IKK) signalsome, a
high molecular weight kinase complex (700 – 900 kD) that contains two catalytic
subunits named IKK1and IKK2 (or IKK a  and IKK b ) (reviewed in (Israel, 2000; Karin,
1999)) and a regulatory subunit termed NEMO, IKKg  or IKKAP (Mercurio et al., 1999;
Rothwarf et al., 1998; Yamaoka et al., 1998) (Figure 1). The exact stochiometry of the
components of the IKK complex is still unknown and might vary between different
cell-types and depend on the activation status of the cell. Ik B-kinase activity is also
found in lysates from activated cells in form of a complex with an apparent molecular
weight of 300 kD. This complex corresponds to dimers of IKK1 and 2, making it
reasonable to assume that the predominant 700 – 900 kD IKK complex consists of a
dimer of IKK1/2 dimers brought together by several NEMO-proteins. It has been
shown, however, that IKK1 and 2 are also active as homodimers (Rothwarf et al.,
1998). IKK1 and IKK2 are highly homologous kinases, consisting of an N-terminal
kinase domain, a helix-loop-helix (HLH) and a leucine zipper (LZ). The kinase
Figure 1. A simplified version of the NF- B Activation Pathway
Proteins are depicted by name and by oval symbols. Receptors are symbolized by
boxed names. Activation processes are indicated by arrows. X stands for
degradation by the 26 S proteosome, P for phosphogroups and Ac for acetylated
amino acid residues. This scheme was composed based on information from:
Karin and Ben-Neriah, 2000; Gosh and Karin, 2002; Li and Verma 2002; Dixit
and Mak, 2002.
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domains are similar to those of other known serine-threonine kinases and contain an
activation loop. In cells stimulated with TNF or IL-1 two serines within this activation
loop become phosphorylated, causing a confirmational change that results in kinase
activation. Replacement of serines 177 and 181 in the activation loop of IKK2 with
alanins prevents activation of IKK, whereas their replacment with glutamic acid (which
mimicks phosphoserine) results in constitutive IKK activity (Rothwarf et al., 1998).
NEMO was cloned independently by genetic complementation of cell lines, which do
not respond to NF- k B activating stimuli (Yamaoka et al., 1998) and as a component of
the purified IKK complex (Mercurio et al., 1999; Rothwarf et al., 1998). It is a 48 kDa
glutamine-rich protein without apparent catalytic activity, which contains a LZ domain,
extended coiled-coil motifs and a putative zinc finger motif.
Recent reports on knockout mice revealed different physiological roles for IKK1 and
IKK2. IKK1-deficient mice die shortly after birth showing skeletal abnormalities and a
thickened hyperproliferative epidermis (Hu et al., 1999; Li et al., 1999a; Takeda et al.,
1999). Lack of differentiation and increased proliferation of ikk1-/- keratinocytes occurs
independently of I k B kinase function and NF-k B activation. IKK1 seems to be
essential for the secretion of an as yet unidentified secreted differentiation factor,
termed kDIF (Hu et al., 2001). Mice containing a kinase-inactive version of IKK1
(IKK1SA) are born at normal mendalian ratios and develop normally. IKK1SA female
mice exhibit defective development of the mammary gland during pregnancy due to
lack of expression of the NF-k B-dependent gene cyclin D1 (Cao et al., 2001).
Stimulation of ikk1-/- mouse embryonic fibroblasts (MEFs) and thymocytes by either
TNF or IL-1 leads to essentially normal NF- k B activation, indicating that IKK1 is
dispensable for induction of Ik B degradation in response to proinflammatory cytokines
(Hu et al., 1999; Li et al., 1999a; Takeda et al., 1999). IKK1 is, however, critical for the
generation of p52 from its precursor p100 (Senftleben et al., 2001a) in response to
inducers such as BAFF (Claudio et al., 2002), LTb  (Dejardin et al., 2002) or CD40
(Coope et al., 2002). Since p100 associates preferentially - but not exclusively - with
RelB (Solan et al., 2002) this pathway mainly induces p52/RelB dimers (Fig 1). In
mammary epithelium IKK1 is also responsible for Ik B degradation and induction of
NF- k B in response to specific signals, such as RANKL (Cao et al., 2001). Recently it
has been found activation of NF- k B can occur independently of NEMO; BAFF induces
processing of p100 to p52 in a NEMO-deficient B cell line (Claudio et al., 2002) and
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LT-beta induces DNA-binding p50 and RelB subunits in the absence of NEMO (Saitoh
et al., 2002).
IKK2 knockout mice die between embryonic days 12.5-14.5 from massive liver
degeneration due to TNF-induced hepatocyte apoptosis (Li et al., 1999b; Li et al.,
1999c; Tanaka et al., 1999), a phenotype similar to that of p65/RelA knockout mice
that die between embryonic days 14.5-15.5 (Beg et al., 1995). NF-k B activation upon
stimulation with TNF or IL-1 is severely impaired in ikk2-/- MEFs, suggesting that
IKK2 is the kinase responsible for NF- k B activation by inflammatory cytokines. IKK2-
knockout mice are viable on a TNFR1-/- background, but the mice still succumb to
opportunistic infections within two to three weeks of birth (Senftleben et al., 2001b).
IKK1 and 2 are required for optimal induction of NF-k B-induced transcription, since
both kinases are involved in phosphorylation of the transactivation domain of the p65
subunit of NF- k B in response to IL-1 and TNF (Sizemore et al., 2002). In addition both
kinases are required for transcription of the majority of NF-k B-dependent genes
activated by these stimuli (Li et al., 2002).
NEMO is essential for NF- k B activation (Rothwarf et al., 1998; Yamaoka et al., 1998),
however, its exact role in the function of the IKK complex remains obscure.
Oligomerization of NEMO is essential for IKK activity (Agou et al., 2002; Li et al.,
2001; Poyet et al., 2000) and numerous studies suggest that NEMO acts by connecting
the IKK to upstream activators (Cooke et al., 2001; Huang et al., 2002; Jain et al.,
2001). The human and mouse genes coding for NEMO are located on the X
chromosome, arranged head to head with the proximal glucose-6-phosphate
dehydrogenase housekeeping gene (G6PD) (Galgoczy et al., 2001; Jin and Jeang,
1999). Three alternative transcripts with different non-coding 5’ exons have been
described. A CpG island, which has been described as essential for the ubiquitous
expression of g6pd (Toniolo et al., 1991), also drives expression of the Nemo gene.
Remarkably, the genes overlap in their 5’ non-coding regions. An alternative Nemo-
promoter has been identified in intron 2 of g6pd. This promoter shows very low basal
activity and may be involved in stress/time- and/or tissue-dependent expression of
NEMO (Galgoczy et al., 2001).
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1.3 Incontinentia Pigmenti
Recently, genetic studies revealed that mutations in the human NEMO gene are the
cause of Incontinentia Pigmenti (IP) or Bloch-Sulzberger Syndrome (Smahi et al.,
2000). IP is an X-linked dominant, male-lethal genetic disorder characterized by
unusual patterns of skin pigmentation (Landy and Donnai, 1993). The skin lesions seen
in IP evolve through characteristic stages, which frequently overlap or appear together.
Affected females show an erythematous, vesicular rash that appears shortly after birth
and is accompanied by massive eosinophilic granulocyte infiltration into the epidermis.
Subsequently verrucous hyperkeratotic lesions evolve that disappear over time, leaving
behind areas of hyperpigmentation in a pattern that respects the lines of Blashko
(Happle, 1985; Landy and Donnai, 1993). In the final stage this hyperpigmentation
fades, and pale hairless patches or streaks remain on the skin (Landy and Donnai,
1993). Another consistent feature of IP is non-random X-inactivation in peripheral
blood leukocytes (PBL). IP patients show completely skewed patterns of X-inactivation
in PBL, suggesting that cells expressing the mutated X-chromosome are counter-
selected (Parrish et al., 1996). Other manifestations of IP include abnormalities of the
teeth, eyes, hair and the central nervous system (Carney, 1976; Landy and Donnai,
1993).
1.4 The Role of the IKK Complex and NF- B in B Cells
Activated NF-k B/Rel proteins are involved in important and diverse functions of B
cells, such as proliferation, isotype switching and cytokine production (Gerondakis et
al., 1998; Grossmann et al., 1999; Gugasyan et al., 2000). NF-k B is constitutively
active in mature B cells indicating that this signaling pathway could be important for B
cell maintenance. Indeed, early studies employing gene targeting technology showed
that mice deficient for more than one of the NF- k B subunits have defects in B cell
development. Adoptive transfer experiments using fetal liver cells of p50/RelA double
knockout mice resulted in absence of B lymphopoiesis. However, when p50-/-RelA-/-
fetal liver cells were mixed with wild-type bone marrow cells they gave rise to mature
B cells in the spleen, demonstrating that this phenotype is non-cell autonomous
(Horwitz et al., 1997). More detailed studies using similar adoptive transfer
experiments of mixed fetal liver cells showed that p50-/- or p50-/-RelA-/- B cells
 Introduction 7
cannot develop into marginal zone (MZ) B cells (Cariappa et al., 2000). Similarly
RelA-/-c-Rel-/- fetal liver cells fail to give rise to IgMlowIgD+ mature B cells. RelA-/-c-
Rel-/- immature (IM) B cells undergo accelerated cell death in culture and express
abnormally low levels of Bcl-2. It remains unclear, however, whether the block in B
cell development in RelA-/-c-Rel-/- mice is due to a cell-autonomous effect or not
(Grossmann et al., 2000). In p50/p52 double knockout mice B cell development is
blocked at the immature stage, at the T1 - T2 transition (Figure 12), shortly after B cells
exit from the BM (Franzoso et al., 1997). Mice deficient for B cell-activating factor
(BAFF), a B cell survival factor expressed on myeoid cells, have an arrest in B cell
development at the same stage as p50/p52 double knockout mice. Subsequently it was
shown that BAFF induces processing of p100 to p52 via one of its receptors on B cells,
BAFFR, and NIK, but independently of NEMO (Claudio et al., 2002). B cell specific
inhibition of NF- k B activity by transgenic expression of a trans-dominant form of I k B-
a  leads to a reduction of mature splenic B cells and recirculating B220highIgM+ bone
marrow cells (Bendall et al., 1999). Mice deficient for p50 have normal numbers of
follicular (FO) B cells (Cariappa et al., 2000). It has been shown, however, that the in
vivo turnover of p50-/- B cells is increased compared to WT B cells (Grumont et al.,
1998; Pohl et al., 2002). Whether this is due to a defect intrinsic to the B cell lineage or
to a defect in other cell-types is not clear. Ex vivo isolated p50-deficient B cells die
faster than wild-type B cells, indicating that p50 could play a role in mature B cell
survival. A direct analysis of whether mature B cells, once generated, depend on NF-
k B mediated survival signals in a cell-autonomous fashion in vivo, has not been
performed so far.
Most signals that activate NF- k B converge at the IKK complex. It has been shown that
B cells lacking IKK1 activity are short-lived and have a reduced capacity to proliferate.
Very few IKK1-deficient B cells develop into IgD+IgMlow mature B cells in the spleen
(Kaisho et al., 2001; Senftleben et al., 2001a). It is controversial whether there is an
overall reduction of NF-k B binding activity in IKK1-deficient B cells (Kaisho et al.,
2001) or whether the maturation defect is solely due to lack of processing of p100 to
p52(Senftleben et al., 2001a). Together with data from BAFF-deficient and p50/p52-
double knockout mice it seems plausible that the B cell defect in Ikk1-/- radiation
chimeras is due to lack of BAFF-induced processing of p100 via NIK and IKK1. Ikk2-
/- radiation chimeras lack peripheral blood B cells (Senftleben et al., 2001b), similarly
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to the p50/p65 double knockout radiation chimeras (Horwitz et al., 1997), but it is not
clear yet whether the inability of IKK2-deficient fetal liver cells to give rise to B cells
is a B cell-autonomous phenomenon or not. In transgenic mice expressing a dominant-
negative version of IKK2 specifically in B cells, B cells develop normally but show
defects in proliferation and antibody responses (Ren et al., 2002b).
Thus, whereas IKK1 is important for the generation of mature B cells, the role of IKK2
is controversial and little is known about the importance of NEMO in B cell
development. Whether activation of NF-k B through IKK is also essential for
maintenance of mature B cells remains unresolved.
1.5 The Role of the IKK Complex and NF- B in T Cells
To address the role of NF- k B in T cells initial studies have employed either targeted
disruption of one or two of the Rel subunits or T cell lineage-specific transgenic
expression of various non-degradable I k B a  mutants (termed superrepressors or
Ik B a DN). Transgenic expression of Ik B a DN  (Boothby et al., 1997; Ferreira et al.,
1999) or of mIk B b  (Attar et al., 1998) directed by the lck-promoter, of Ik B a DN
directed by the CD2-promoter  (Hettmann et al., 1999), or of human I k B a  under
control of a b -globin promoter/CD2 enhancer contruct (Esslinger et al., 1998; Esslinger
et al., 1997) led to a reduction of peripheral T cells to varying degrees, probably
reflecting differences in promoter strength and specificity and of the Ik B repressor
used. One common feature of these mice is that CD8 cells are more diminished then
CD4 cells. The remaining T cells in these different mice have defects in proliferative
responses, in IL-4, IL-10 and INFg  secretion (Aune et al., 1999; Ferreira et al., 1999)
and they are more susceptible to Fas - and activation-induced apoptosis in vitro (Aune
et al., 1999; Boothby et al., 1997; Ferreira et al., 1999). Treatment of quiescent human
blood lymphocytes with pharmacological NF- k B inhibitors in vitro induced slow T cell
apoptosis associated with a gradual downregulation of Bcl-2 (Bureau et al., 2002).
Studies using knockout mice revealed the roles of individual Rel proteins in T cell
activation (reviewed in (Caamano and Hunter, 2002; Denk et al., 2000)). p50-/-p52-/-
double knockout mice lack mature T cells and radiation chimeras reconstituted with
p50-/-RelA-/- fetal liver cells show complete absence of lymphopoiesis. In both cases,
however, adoptive transfer experiments showed that these defects are not cell-
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autonomous but rather track with cells outside the T lineage (Franzoso et al., 1997;
Horwitz et al., 1997). Analysis of mice engrafted with c-Rel/RelA double knockout
fetal liver cells showed a deficit of peripheral T cells, which could not be rescued by
the enforced expression of the survival factor bcl-2 (Grossmann et al., 2000). It is not
clear, however, whether the defect seen in c-Rel-/-RelA-/- fetal liver chimeras is based
on a T cell-autonomous requirement for NF-k B or not. These studies demonstrate that
interference with NF-k B activation in various ways leads to diminished mature T cell
populations with impaired functions. They also show, however, that peripheral T cells
with impaired NF-k B function can be generated and sustained in vivo.
Mice lacking RelA or IKK2 die early in embryogenesis displaying dramatic TNF-
induced destruction of the liver (Beg et al., 1995; Li et al., 1999b; Li et al., 1999c;
Tanaka et al., 1999). Similarly to p50-/-RelA-/- fetal liver cells also IKK2-deficient
fetal liver cells failed to reconstitute mature T cells in irradiated hosts. Also in this case
co-transfer experiments showed that the defect is not due to a cell-autonomous
requirement of IKK2 in T cells. In addition, IKK2-/-TNFR-/- double knockout mice,
which are viable and reach 3-4 weeks of age, show nearly normal thymocyte
development leading to the suggestion that defective T cell development in chimeras
reconstituted with IKK2-deficient fetal liver is caused by TNF induced killing of
thymocytes (Senftleben et al., 2001a). Adoptive transfer experiments showed that
peripheral T cells develop in the absence of IKK1 (Kaisho et al., 2001; Senftleben et
al., 2001a). Transgenic expression of dominant-negative versions of IKK1 or IKK2
under the control of the human CD2 promoter did not interfere with the development of
splenic CD4 and CD8 T cells. Even co-expression of dominant-negative IKK1 and 2
had no overall effect on T cell development (Ren et al., 2002a).
Thus lack of either IKK1 or IKK2 in T cells does not interfere with the generation of
mature T cells; nor does simultaneous dominant-negative interference with IKK1 and 2
signaling. These data suggest that the IKK does not play an important role in T cell
development. Mice in which NF-k B activation is inhibited by transgenic expression of
non-degradable Ik B proteins have reduced T cell numbers. This suggests that either
NF- k B activation can occur in absence of IKK signaling in T cells or that IKK1 and 2
can compensate for the lack of the other.
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1.6 Objectives
When I started this project IKK1, 2 and NEMO had just been cloned and nothing was
known about their roles in vivo . In view of the high overall redundancy in the NF-k B
signaling pathway, the inactivation of the Nemo gene appeared to me as uniquely suited
to completely block NF-k B activation by a single gene knockout. RelA knockout mice
die around embryonic day 15 due to extensive liver degeneration and it seemed
possible that NEMO knockout mice would have a similar phenotype. The assessment
of the role of genes in tissues of adult mice is impossible in knockout mice with early
embryonic lethality. I opted to circumvent this problem by using the approach of
conditional gene targeting, which allows the deletion of genes in specific cell types of
the adult mouse (Rajewsky et al., 1996). Therefore I decided to generate a conditional
nemo allele (nemoFL) in order to analyze the role of NEMO and NF-k B in mouse
development and immune cells. The complete blockade of NF- k B signaling by removal
of NEMO was to be compared to the lack of IKK2 activity, through side by side
comparison of the newly generated nemoFL mice with available IKK2 conditional
mouse strains.
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2 MATERIALS AND METHODS
2.1 Molecular Biology Methods
Common methods of molecular biology were performed according to standard protocols
(Sambrook et al., 1989). Enzymes were obtained from the following companies:
Boehringer Mannheim (Mannheim), GIBCO-BRL (Gaithersburg, USA), NEB (Beverly,
USA), Stratagene (USA), Takara (Japan) and USB (Cleveland, USA). Size markers for
agarose gel electrophoresis were obtained from GIBCO-BRL (1 kb marker, l-HindIII
marker).
2.1.1 Competent Cells and Isolation of Plasmid DNA
Competent Escherichia coli DH5 a  cells were prepared according to the protocol of Inoue
et al. (Inoue et al., 1990) and used in heat shock transformations of plasmid DNA. Rapid
DNA ligation was performed with the Takara DNA Ligation Kit (Takara, Japan) according
to the manufacturers instructions.
Plasmid DNA was isolated from transformed Escherichia coli DH5 a  bacteria with an
alkaline lysis method (Birnboim, 1983). The procedure was according to the protocol of
(Zhou et al., 1990). Plasmid DNA of a higher purity was obtained with QIAGEN columns
(QIAGEN, Hilden) following the supplier's instructions.
2.1.2 Isolation of Genomic DNA from ES Cells and Mouse Organs
Cells were lysed over night at 37°C in lysis buffer (10 mM Tris-HCl, pH 8; 10 mM EDTA;
150 mM NaCl; 0.2% SDS; 400 mg/ml Proteinase K). Subsequently, DNA was precipitated
from the solution by the addition of an equal volume of Isopropanol. The DNA was
pelleted by centrifugation, washed in 70% EtOH and resuspended in TE-buffer (10 mM
Tris-HCl, pH 8; 1 mM EDTA). From ES cell clones, that were grown in 96-well tissue
culture dishes, DNA was extracted and prepared according to the protocol of (Pasparakis
and Kollias, 1995).
Mouse tissue was incubated for 5 h to o/n at 56°C in lysis buffer (0.1 M Tris-HCl, pH 8.5;
5 mM EDTA; 0.2% SDS; 0.2 M NaCl; 600 mg/ml Proteinase K). Undissolved debris was
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pelleted and the supernatant was mixed with an equal volume of isopropanol to precipitate
the DNA. The DNA was washed in 70% EtOH, dried and resuspended in ddH2O.
2.1.3 Agarose Gel Electrophoresis and DNA Gel Extraction
Separation of DNA fragments by size was achieved by electrophoresis in agarose gels
(0.7% - 2.5%; 1 x TAE (Sambrook et al., 1989); 0.5 mg/ml ethidiumbromide). DNA
fragments were recovered from agarose gel slices with either the QIAEX II or the
QIAquick Gel Extraction Kit (QIAGEN, Hilden) following the manufacturer's protocols.
2.1.4 DNA Sequencing
DNA fragments were sequenced with the 'Taq DyeDeoxyTerminator Cycle Sequencing
Kit' (Applied Biosystems), which is a PCR-based modification of the Sanger et al. (Sanger
et al., 1977) protocol. The fluorescently labelled DNA pieces were separated and analysed
with ABI373A and ABI377 systems (Applied Biosystems) with the help of S. Wilms.
Sequencing of the murine Nemo locus was in part performed by Exelixis.
2.1.5 Quantitation of DNA
The concentration of nucleic acids was determined by measuring the absorption of the
sample at 260 nm and 280 nm in a spectrophotometer (Pharmacia). An OD260 of 1
corresponds to approximately 50 m g/ml for double stranded DNA or 40 m g/ml for RNA
and single stranded DNA. Purity of nucleic acids can be estimated by the ratio
OD260/OD280, pure preparations of DNA and RNA show a ratio of 1.8 and 2.0,
respectively. Alternatively, the DNA sample was electrophoresed in an agarose gel, and
the concentration was estimated from the band intensity in comparison with a standard.
2.1.6 Polymerase Chain Reaction (PCR)
PCR (Mullis and Faloona, 1987; Saiki et al., 1985) was used to screen mice and ES cells
for the presence of targeted alleles or transgenes and to amplify fragments for sequencing.
Reactions were performed either in Hybaid machines (MWG-Biotech) or Trio-
thermocyclers (Biometra).
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Name Sequence (5’-3’) TAnn. [° C] Location Direction
27 GCCTTGGTGCTCCCTAACTCT 62 Nemo intron2 sense
39 GATTCGCAGCGCATCGCCTT 62 neor anti-sense
40 TCACATCACATCGTTATCCTT 62 Nemo intron2 anti-sense
61 ATGAACAAGCACCCCTGGAAG 62 Nemo exon1 sense
MP65 GTTCAGAGGTTCAGTCCATTATC 60 Ikk2 intron 5 sense
MP45 TAGCCTGCAAGAGACAATACG 60 Ikk2 exon 6 anti-sense
MP49 TCCTCTCCTCGTCATCCTTCG 60 Ikk2 intron 6 anti-sense
M35 GACAAGCGTTAGTAGGCACAT 60 Flpe6 sense
M36 GAGAAGAACGGCATAGTGCGT 60 Flpe6 anti-sense
Cre1 CATCGCCATCTTCCAGCAG 62 Cre sense
Cre2 CAATTTACTGACCGTACAC 62 Cre anti-sense
Cre8 CCCAGAAATGCCAGATTACG 60 Cre sense
CD19c AACCAGTCAACACCCTTCC 60 neor anti-sense
Table 1.  List of primers routinely used for typing
The sequences are shown from 5’ to 3’. Direction is designated “sense”, if the primer
orientation coincides with the transcriptional orientation of the adjacent gene, and “anti-
sense” otherwise.
Genotyping of mice and ES cells was generally performed in a total volume of 30 ml
according to the following reaction mix: 25 pMol of each primer, 1.6 U of Thermus
aquaticus (Taq) DNA polymerase (GIBCO-BRL), 250 mM dNTPs (Pharmacia), 10 mM
Tris-HCl pH 8.3, 50 mM KCl, 2.5 mM MgCl2, 100 ng template DNA. Amplification
started with denaturation for 3 min at 94 °C followed by 30-35 cycles of 94 °C for 30 sec,
59-62 °C for 30 sec and 72 °C for 30 sec. A final extension step was performed at 72 °C
for 5 min.
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Primers Mouse Strain Allele Product [Bp]





M35, M36 Flpe6 Flpe 647
MP65, MP45, MP49 Ikk2-conditional WT 436
FL 533
D 652
Cre1,Cre2 All Cre lines Cre 1000
Cre8, Cre19c CD19-Cre CD19-Cre 525
Table 2. Mouse typing by PCR
Since Pfu DNA polymerase (Stratagene) has a 12-fold higher fidelity than Taq DNA
polymerase, it was used for amplification of fragments for sequencing. PCR of transgenic
Cre lines was performed as published.
2.1.6 Southern Blot Analysis
5-15 m g DNA were digested o/n with 50 to 100 U of the appropriate restriction enzyme.
Subsequently, the DNA fragments were resolved by agarose gel electrophoresis and
transferrred onto HybondTM-N+ (Amersham) or GeneScreenPlus (Dupont) nylon
membranes by an alkaline capillary transfer according to the method of (Chomczynski and
Qasba, 1984). Membranes were baked at 80°C for 2 hours to fix the DNA, equilibrated in
2x SSC (Sambrook et al., 1989) and then prehybridized o/n in hybridization solution (1M
NaCl, 1% SDS, 10% dextran sulfate, 50 mM Tris-HCl pH 7.5, 500 m g/ml sonicated
salmonsperm DNA) at 65 °C. Afterwards, the radioactively labelled probe was added to
the hybridization solution and allowed to hybridize for 10 h at 65 °C in a rotating cylinder
(Hybaid).
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The following probes were used:
Nemo 5' external probe (probe A): A 480 Bp fragment, excised with AccI and XmnI
from DNA2 (Schmidt-Supprian et al., 2000). DNA2 contains a cloned
BamHI fragment of the Nemo genomic locus, the AccI-XmnI 480 Bp
fragment is located before exon 1 of the Nemo gene.
Nemo 3' external probe: A 429 Bp fragment, excised with SpHI and EcoRI from DNA1
(Schmidt-Supprian et al., 2000). DNA6 contains a cloned BamHI fragment
of the Nemo genomic locus, the SpHI-EcoRI 429 Bp fragment is located in
intron 5 of the Nemo gene.
Nemo internal probe (probe B): A 597 Bp fragment, excised with SpHI and EcoRI from
DNA2 (Schmidt-Supprian et al., 2000). DNA2 contains a cloned BamHI
fragment of the Nemo genomic locus, the SpHI-EcoRI 597 Bp fragment is
located in intron 2 of the Nemo gene.
Ikk2 internal probe: A BglII-StuI fragment (Pasparakis et al., 2002a).
neor probe: A fragment of 600 Bp, excised as a PstI – BamHI fragment from
pMMneoflox8 (Kraus, 2001).
25 to 60 ng of sample DNA were radioactively labeled with 2.5 mC [a 32P]dATP
(Amersham, Braunschweig) using the LaddermanTM Labeling Kit (Takara, Japan) that is
based on the principle of random primed oligolabeling (Feinberg and Vogelstein, 1984).
Unincorporated radiolabeled nucleotides were removed with MicroSpinTM S-200HR
columns to reduce background during hybridization (Pharmacia). The probe was denatured
for 5 min in a boiling waterbath before it was added to the hybridization solution. After
hybridization stringency washes were initially performed twice in 1 x SSC/0.1 % SDS and
then followed by washes in 0.5 x SSC/0.1 % SDS and 0.25 x SSC/0.1 % SDS, if necessary.
All washes were at 65 °C under gentle agitation for 15 min to 1 hour. After each wash the
filter was monitored with a Geiger-counter. The washes were stopped when specific
signals of 20 to 100 cps were detectable. Then, the filter was sealed in a plastic bag and
exposed to X-ray film (Kodak XAR-5 or BioMAX MR; Eastman Kodak) at –70 °C. Film
was developed in an automatic developer (Agfa). Alternatively, the filter was exposed at
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RT to a phosphoimager screen (Fuji) that was analyzed on a Bio-Imaging Analyser (Fuji
Bas 1000; Fuji, Japan).
2.2 Cell Biology Methods
2.2.1 Embryonic Stem Cell Culture
The conditional allele nemoFL was generated with Bruce-4 ES cells (Kontgen et al., 1993)
Culturing and transfection of ES cells was performed according to published protocols
(Pasparakis and Kollias, 1995; Torres and Kuehn, 1997). To maintain the pluripotency of
the ES cells, they were cultured in the presence of LIF containing ES cell medium on a
layer of embryonic feeder (EF) cells. The ES cell medium (DMEM, 15 % FCS, 1 mM
sodium pyruvate, 2 mM L-glutamine, 1 x non essential amino acids, 1:1000 diluted LIF
supernatant, 0.1 mM 2-b -mercaptoethanol) contained FCS from a batch that had been
tested to promote ES cell growth and hinder in vitro differentiation. ES and EF cells were
grown in tissue culture dishes (Falcon, Greiner) and kept at 37°C in a humid atmosphere
with 7.5% CO2. EF cells (EF medium: DMEM, 10% FCS, 1 mM sodium pyruvate, 2 mM
L-glutamine) were never passaged more than three times and mitotically inactivated by
mitomycin-C treatment (10 m g/ml for 2 h), prior to seeding with ES cells. ES cell colony
growth was stopped before they became confluent. Colonies were washed once with PBS
and then treated shortly with trypsin (0.05 % trypsin, 0.02 % EDTA in PBS; GIBCO-BRL)
at 37°C until the cells detached from the dish. Optimal conditions for trypsinization of
Bruce-4 cells were achieved by supplementing the solution with 1% chicken serum. The
cell suspension was then used for passaging, transfection or freezing. ES cells were frozen
in ES cell medium containing 10 % DMSO at –80°C and later transferred into liquid
nitrogen for long term storage. For transfection, 0.6 - 1 x 107 ES cells were mixed with 30
to 40 m g of DNA in 1 ml transfection buffer (20 mM HEPES, pH7; 137 mM NaCl; 5 mM
KCl; 0.7 mM Na2HPO4; 6 mM Glucose; 0.1 mM 2-b -ME) and electroporated at RT (480
mF, 230-240V). Subsequently, the ES cells were transferred onto an embryonic feeder
layer and 48 hours later placed under G418 selection (300 m g/ml, 50% active). Selection
against HSV-tk containing random integrants started at day five after transfection by
supplementing the medium with 2 mM gancyclovir (Cymeven, Syntex). At around day 10
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of the transfection, double resistant colonies were picked and split into EF-containing 96-
well tissue culture dishes for expansion.
Specific deletion of the loxP flanked exon II of the Nemo gene and the FRT flanked neor
selection marker cassette from targeted ES cells was achieved in a transient transfection
with 30 m g of supercoiled plasmids: either pCMV-Flpe6 (Buchholz et al., 1998) and
pPGK-Puro, or pCMV-Flpe6, pPGK-Cre (K. Fellenberg, unpublised) and pPGK-Puro
(pFlep6, pPGK-Cre and pPgk-Puro in a ratio of 1:1:10). The conditions of the transfection
were as described above. Two days after the transfection the ES cells were split and
replated at a density of 2 x 103 cells per 10 cm tissue culture dish. Within the next seven to
ten days colonies were allowed to grow up, before they were picked, trypsinized and split
into a master and a duplicate 96-well plate. Cells in the duplicate plate were placed under
G418 selection (700 m g/ml, 50% active) such that G418 sensitive clones were detectable
by cell death. The sensitive clones were then recovered and expanded from the master
plate.
2.2.2 Preparation of Cell Suspensions from Lymphoid Organs
Ex vivo isolated cells were resuspended in medium (DMEM, 5% FCS, 2 mM L-glutamine)
and kept on ice. Thymus, spleen and lymph nodes were squashed between two frosted
sides of a microscope slide to obtain single cell suspensions. Bones were flushed with
medium to extract bone marrow cells and the peritoneal cavity was flushed with 10 ml of
medium to recover cells. Erythrocytes were lysed from spleen and bone marrow
preparations by incubation in lysis buffer for 2 min on ice (140 mM NH4Cl, 17 mM Tris-
HCl pH7.65). Blood from the tail vain was collected in a tube with heparin (Liquemin,
Roche) and then layered on top of 7% Ficoll 400 (Pharmacia, Sweden). After
centrifugation at RT with 1350 g for 15 min., lymphocytes were recovered from the
interphase of the gradient.
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2.2.3 Flow Cytometry
Cells (in general: 106 per sample) were surface stained in 30 ml PBS, 1 % BSA, 0.01 % N3
with combinations of fluorescein isothiocyanate (FITC), phycoerythrin (PE), Cy-
ChromeTM (Cyc), PERCP and/or APC conjugated mAbs for 20 min on ice. Stainings with
biotinylated mAbs were followed by a second staining with either Streptavidin-Cy-
ChromeTM (Pharmingen) or Streptavidin-PERCP (Becton Dickinson). After staining the
samples were washed and resuspended with PBS-BSA-N3. Stained cells were acquired on
a FACScan or FACSCalibur and data were analysed using CellQuest software (Becton
Dickinson). Dead cells were labelled with propidium iodide or Topro-3 and excluded from
the analysis. Monoclonal antibodies, listed in Table 3, were either prepared in our
laboratory by C. Uthoff- Hachenberg and B. Hampel or purchased from Pharmingen
(USA).
Specificity Clone     Reference and supplier
IgM R33-24.12 (Gruetzman, 1981), lab-made
IgD 1.3-5 (Roes et al., 1995), lab-made
IgMb MB86 (Nishikawa et al., 1986), lab-made
IgG2ab G12-47/30 (Seemann, 1981), lab-made
IgG2b R14-50 (Müller, 1983), lab-made
IgE 95.3 (Baniyash and Eshhar, 1984), lab-made
NP B1-8m (Reth, 1981), lab-made
NP B1-48 (Reth, 1981), lab-made
NP S43-10 (Wildner, 1982), lab-made
NP S24/63/63 (Baumhackel et al., 1982), lab-made
NP N1G9 (Cumano and Rajewsky, 1985), lab-made
NP B53-8 (Reth, 1981), lab-made
NP B53-12 (Reth, 1981), lab-made
B220/ CD45R RA3-6B2 (Coffman, 1982), lab-made/Pharmingen
CD3e 145-211 (Leo et al., 1987), Pharmingen
CD4 GK.1.5/4 (Dialynas et al., 1983), Pharmingen
CD5 53-7.3 (Ledbetter and Herzenberg, 1979), Pharmingen
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CD8 53-6.7 (Ledbetter and Herzenberg, 1979), Pharmingen
CD11c HL3 (Huleatt and Lefrancois, 1995), Pharmingen
CD11b (Mac-1) M1/70 (Springer et al., 1979), lab-made/Pharmingen
CD19 1D3 (Krop et al., 1996), Pharmingen
CD21/CD35 7G6 (Kinoshita et al., 1988), Pharmingen
CD22 Cy34.1 (Symington et al., 1982), Pharmingen
CD23 B3B4 (Rao et al., 1987), Pharmingen
CD24/HSA M1/69 Springer et al. 1978, Pharmingen
CD25 (IL2Ra ) 7D4 (Malek et al., 1983), Pharmingen
CD43 S7 (Gulley et al., 1988), Pharmingen
CD44 KM114 (Miyake et al., 1990), Pharmingen
CD45Rb 16A (Bottomly et al., 1989), Pharmingen
CD62L (L-Selectin) MEL-14 (Gallatin et al., 1983), Pharmingen
CD69 H1.2F3 (Yokoyama et al., 1988), Pharmingen
CD86/B7.2 GL1 (Inaba et al., 1994), Pharmingen
CD90/Thy1.2 CFO-1 (Opitz et al., 1982), Pharmingen
CD95 (Fas) Jo2 Pharmingen
CD103 ( a IEL) M290 (Kilshaw and Baker, 1988), Pharmingen
CD152 (CTLA-4)  UC10-4F10-11 (Tivol et al., 1995), Pharmingen
I-Ab AF6-120.1 (Wall et al., 1983), Pharmingen
H-2Kb AF6-88.5 (Loken and Stall, 1982), Pharmingen
H-2Kd SF1-1.1 (Abastado et al., 1987), Pharmingen
Ly6-G (Gr-1) RB6-8C5 (Fleming et al., 1993), Pharmingen
MHC class II M5/114 (Bhattacharya et al., 1981), Pharmingen
BP-1 BP-1 (Cooper et al., 1986), Pharmingen
HSA 30F1 (Ledbetter and Herzenberg, 1979), lab-made
TCRb H57-597 (Kubo et al., 1989), Pharmingen
Table 3. List of antibodies used for flow cytometry and ELISA.
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2.2.4 Magnetic Cell Sorting and FACS Sorting
Specific cell populations were either sorted or depleted from a heterogenous cell
suspension by magnetic cell sorting (MACS; Miltenyi Biotec, Bergisch Gladbach). Cell
populations were labelled with antibody-coupled microbeads (10 ml beads, 90 ml PBS-
BSA-N3 per 10
7 cells) and separated on VS, CS or Mini-MACS columns in a magnetic
field (Miltenyi et al., 1990). For cell sorting B cells were purified by MACS (Miltenyi) and
then stained with antibodies against various cell surface markers. B cells of individual B
cell subsets were then sorted using a dual laser FACStar (Becton Dickinson). The purity of
isolated populations was subsequently tested by FACS analysis: MACS-isolated B cells
were typically ³  85% pure and sorted B cell subpopulations were ³  95% pure. FACS
sorting was performed with the help of Christoph Goettlinger.
2.2.5 CFSE Labeling and in vitro T Cell Activation
T cells were purified using MACS (CD90- or CD4-beads after depletion with B220- or
CD19-beads, all Miltenyi) or R&D T cell enrichment columns or FACS-sorting. For
activation marker studies 1.5 to 4 x 106 cells were plated in a 24 well plate and analyzed
after 24 h. Supernatants were kept for cytokine analysis. For proliferation T cells were
resuspended in 1 ml per 107 cells 2.5 µM CFSE (5 mM stock in DMSO, Molecular Probes)
in PBS at 37 °C for 5min (Lyons and Parish, 1994). The labeling reaction was stopped by
addition of 10 ml ice-cold DMEM/10 % FCS medium. The cells were then washed once in
medium. Labeled T cells were plated at 0.5 x 106 cells per well in round bottom 96 well
plates and analyzed after various time points.
Stimulations with immobilized antibodies against CD3 (Clone 145-2C11, Pharmingen) or
CD3 and CD28 (Clone 37.51, Pharmingen) were performed either by precoating plastic
plates with antibody or by adding antibody-coated beads to the cell suspensions. Beads
(surfactant-free sulfate white polystyrene latex, 4.9 m m diameter, intrafacial dynamics
corporation) were incubated with the antibodies in PBS at 37 ° C rotating for 2h, washed
twice with PBS and resuspended in medium.
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2.3 Biochemistry and Immunohistochemistry
3.2.1 Protein Extract Preparations
MEFs were resuspended at 106/15 m l cells in hypotonic solution (10 mM Hepes [pH 7.9],
10 mM KCl, 2 mM MgCl2, 0.5 mM DTT, 0.1 mM EDTA, supplemented with various
protein inhibitors) and incubated for 10 min at 4 ° C. Then NP-40 was added to 10 % and
the cells were microfuged at 13,000 rpm for 1 min. The supernatant containing the
cytoplasmic fraction was recovered and the nuclear pellet was resuspended in 106/10 m l
cells of high salt buffer (20 mM Hepes [pH 7.9], 420 mM NaCl, 1.5mM MgCl2, 0.5 mM
DTT, 0.2 mM EDTA
and 10 % glycerol) and incubated on ice for 30 min. Nuclear extracts were recovered after
centrifugation at 10,000 rpm for 10 min at 4 ° C and stored at – 80 ° C.
3.2.2 Western Blotting
Cytoplasmic extracts were electrophoresed by SDS-PAGE (10 %) and transferred to
immobilon-NC membranes (Millipore). The membranes were blocked with superblock
(Pierce), or 3 % NF-milk/PBS or 5 % BSA/PBS and probed using various antibodies.
Membranes were then incubated with goat anti-rabbit IgG-horseradish peroxidase (HRP)
conjugates and developed using the ECL or ECL+ kit (APB).
Specificity Clone, Manufacturer 
b -Actin (AC-15, Sigma)
G6PD (A 9521, Sigma)
Ik Ba  (C21, Santa Cruz)
IKK1 (IMG-136, Imgenex)
IKK2 (10AG2, Upstate Biotechnology)
IKK2 (AHP547, Serotec)
NEMO (rabbit anti-NEMO serum, Yamaoka et al, 1998)
SHP-2 (sc-280; C-18, Santa Cruz)
Table 4. List of antibodies used for Western Blotting
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3.2.3 Electromobility Shift Assay
1 m g to 5 m g of nuclear extract (for MEFs) or NP-40 whole cell lysate (for sorted T cells)
were incubated for 30 min at room temperature with 2 m g poly(dI-dC) (Pharmacia) and 0.5
ng of 32P-labelled k B probe derived from the H-2Kb promoter (Yamaoka et al., 1998) in
binding buffer (10 mM TrisHCl [pH 7.5], 50 mM NaCl, 0.5 mM DTT, 0.1 mM EDTA, 0.1
mg/ml BSA and 4 % glycerol). Samples were fractionated on a 5 % non-denaturing PAGE
and visualized by autoradiography. Other probes used were NF-k B (Promega), Oct-1
(Promega) and NF-1 (Rothwarf et al., 1998).
For supershift assays nuclear extracts or whole cell lysates were preincubated for 30 min at
RT with antibodies against p50 (sc-114, Santa Cruz), p52 (rabbit antiserum, upstate
biotech), RelA (sc-109, Santa Cruz), c-Rel (sc70, Santa Cruz) or RelB (sc-226; C-19,
Santa Cruz).
3.2.4 Measurement of IL-6 and TNF Production
MEFs were plated at 4 x 104 cells per well onto 48 well plates in DMEM containing 10 %
FCS. After 24 h cells were stimulated in triplicate samples with 1 or 10 ng/ml IL-1b , 10
ng/ml TNF or 1 m g/ml LPS for 16 h. The concentration of IL-6 and TNF in the culture
supernatant was determined by ELISA (R&D Systems), according to manufacturer’s
instructions.
3.2.5 Measurement of TNF-Induced Cell Death
MEFs (2 x 104 cells per well) were plated onto 96 well plates and cultured for 24 h in
DMEM containing 10 % FCS. Then the cells were stimulated in DMEM containing 5 %
FCS with either 10 ng/ml TNF or 10 ng/ml TNF plus 300 ng/ml Cycloheximide (Tanaka et
al., 1999). TNF induced cell death was determined by a celldeath kit (Promega) according
to manufacturers instructions. Each condition was measured in triplicate samples.
3.2.6 Preparation of Thin and Ultrathin sections
Tissues fixed in 4 % paraformaldehyde were subsequently treated with 2 % osmium
tetroxide in 0.1 M PBS for 2 h at 4°C, washed in 0.1 M PBS, dehydrated in a graded
ethanol series and embedded in araldite. The 0.5 µm thin slices were stained with
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methylene blue and investigated using a Zeiss Axiophot (Zeiss). Ultrathin 60 nm sections
were examined using an electron microscope (902A, Leo) after further contrasting with
uranyl acetate-lead citrate. Sections were cut by B. Hampel, C. Hoffmann, E. Janßen, and
J. Siodladczek.
3.2.7 Histological Analysis and Immunohistochemistry
Paraffin sections were cut at 5-10 µm and stained with hematoxylin and eosin or giemsa-
azur-eosin-methylene blue solution (Merck). Immunohistochemistry was performed on
paraffin sections using antibodies against NOS-II (SA200, Biomol), Ki-67 (Dianova) and
the 85 kD cleavage fragment of PARP (Promega). After treatment with 3 % normal goat
serum sections were incubated with the second antibody (Dako). The histological analysis
was done in collaboration with Wilhelm Bloch (Institut I für Anatomie, Joseph Stelzmann
Strasse 9, D-50931 Köln, Germany).
2.4 Mouse Experiments
Mouse experimental procedures like vasectomy of males, tail bleeding as well as breeding
of foster mothers and the general handling, marking of mice were performed according to
Hogan (Hogan et al., 1987) and Silver (Silver, 1995).
2.4.1 Mice
C57BL/6, C57BL/6 x Balb/c, 129/Sv and CD1 mice were obtained from Bomholtgard
(Denmark), Charles River, Harlan Winkelmann or Jackson Laboratories. CB20 mice were
taken from breedings in our animal facility. Balancer-Cre mice (Betz et al., 1996), CD4-
Cre (Lee et al., 2001), CD19-Cre mice (Rickert et al., 1995; Rickert et al., 1997), deleter-
Cre mice (Schwenk et al., 1995) and Mx-Cre mice (Kuhn et al., 1995) were intercrossed
with the newly generated NemoFL strain, the Ikk2FL (Pasparakis et al., 2002a) and the
Ikk2 KFL (Pasparakis et al., 2002b) in conventional facilities.
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2.4.2 Immunizations
Primary T dependent antigen responses were induced with alum precipitated NP-CG (4-
hydroxy-3-nitrophenylacetyl chicken-g - globulin) (Weiss and Rajewsky, 1990). The
immunogen was prepared by mixing 1 volume of (1 mg/ml in PBS) with 1 volume of 10 %
KAl(SO4)2. The solution was adjusted to pH 6.5 and kept 30 min on ice. Then, the
precipitate was washed three times in PBS and resuspended in PBS. Mice were immunized
by i.p. injections of 5 or 50 m g NP17-CG in a volume of 200 m l.
2.4.3 ELISA - Serum Analysis
Ig serum concentrations were determined by C. Uthoff-Hachenberg with enzyme-linked
immunosorbent assays (ELISA, (Kendall et al., 1983)) as described in Roes and Rajewsky
(Roes and Rajewsky, 1993). Microtiter plates (Costar) were coated in PBS plus reagent at
4 °C o/n, and subsequently blocked at RT for 30 min in PBS, 0.5 % BSA, 0.01 % N3, pH
7.2. Next, serially diluted sera samples were applied to the wells and incubated at 37 °C for
1 hour. Then, secondary biotinylated antibody was added for 1 hour at 37 °C. Detection of
the biotinylated reagent was achieved with SA-conjugated alkaline phosphatase (AP,
Boehringer: 30 min at RT) and p-nitrophenylphosphate as substrate (Boehringer).
Following each incubation step, unbound antibodies or SA-conjugated AP were removed
by five washes with tapwater. The OD405 was measured with an ELISA-photometer
(Anthos 2001, Anthos Labtech Instruments) and the relative antibody concentrations were
determined by to a standard. Affinities of IgG1 and l NP-specific antibodies were
determined by calculating the association constant as described by Cumano and Rajewsky
(Cumano and Rajewsky, 1986), following a method developed by Herzenberg et al.
(Herzenberg and Black, 1980). Relative binding of serum antibodies to NP5-BSA versus
NP14-BSA was determined by ELISA in comparison to anti-NP antibody standards of
known affinity.
Coating Biotin-Conjugate Specificity Standard
R33-24.12 gam IgM (SBA) IgM B1-8m
RS 3.1 R33-60 IgMa 267.7
Mb86 R33-60 IgMb B1-8m
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gam IgG1 (Sigma) gam IgG1 (SBA) IgG1 N1G9
ram IgG2aa (Nordic) gam IgG2a (SBA) IgG2aa 41.2-3
G12-47/30 G12-47/30 IgG2ab S43-10
R14-50 gam IgG2b (SBA) IgG2b D3-13F1
2E.6 gam IgG3 (SBA) IgG3 S24/63/63
gam IgA (Sigma) gam IgA (SBA) IgA 233.1.3
95.3 ram IgE (Pharmingen)IgE B1-8e
187.1 R33-18-10.1 k  S8
NP-BSA gam IgM (SBA) NP/IgM B1-8m
NP-BSA RS3.1 NP/IgMa 267.7
NP-BSA MB86 NP/IgMb B1-8m
NP-BSA gam IgG1 (SBA) NP/IgG1 N1G9
NP-BSA gam IgG2a (SBA) NP/IgG2a S43-10
NP-BSA gam IgG3 (SBA) NP/IgG3 S24/63/63
NP-BSA gam l  (SBA) / LS136 NP/ l  N1G9
NP-BSA gam k  (SBA) NP/ k  S8
Table 5. Antibody combinations to determine serum antibody isotypes.
2.4.4 BrdU Labeling
Mice were fed with BrdU (Sigma-Alrich) in the drinking water (1 mg/ml) for one or two
weeks (Forster et al., 1989; Gray, 1988). Splenocytes were stained with FITC-conjugated
anti-B220 mAbs (clone RA33.A1.CL6) and fixed with 70 % methanol followed by 2 %
formalin in PBS. Cell were then treated with 1M HCl/0,5 % Tween 20 for 15 min at 37 oC
followed by 0, 1 % Na2B4O7. Cells were finally stained with a biotin-conjugated anti-BrdU
mAb (Alexis Biochemicals) and streptavidin-Cychrome and analyzed with a FACSCalibur
(Becton Dickinson). Alternatively BrdU-Incorporation was measured using a
commercially available kit following manufacturers instructions (Pharmingen).
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2.4.5 Anti IL-7R Antibody Injections
Mice were injected intravenously with 1 mg of anti-IL-7R mAb (clone A7R34) (Sudo et
al., 1993) every other day for four weeks before sacrifice. Cell suspensions from the
various lymphoid organs were analyzed by FACS. DNA isolated from MACS-purified
splenic B cells was analyzed with Southern blotting.
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3. RESULTS
3.1 Generation of a Conditional nemo Allele
The murine gene encoding NEMO is located on the X chromosome, less than 4 kb
from the G6pd gene (Figure 2A). Two BamHI fragments from a BAC containing the
murine Nemo gene were subcloned and sequenced and found to contain the first 7
coding exons of Nemo and the entire region between the coding sequences of the Nemo
and G6pd genes: DNA 2 (6.7 kb, containing Nemo exons I and II) and DNA 1 (7.6 kb,
encompassing exons III-VII) (Figure 2). For the generation of NEMO-deficient mice a
conditional nemo allele was produced. Deletion of exon II introduces a frameshift
followed by a premature termination codon, and should thus inactivate the Nemo gene.
In order to test this hypothesis a Nemo cDNA lacking exon 2 was cloned and expressed
in a NEMO-deficient B cell line (Yamaoka et al., 1998). Expression of this cDNA
failed to restore NF-k B activation in this cell line, showing that deletion of exon 2
indeed leads to a nemo null allele (data not shown).
Therefore I decided to place Nemo exon II between two loxP sites in the mouse
genome. Accordingly a targeting vector was designed to flank exon II of Nemo with
two loxP sites: A FRT site flanked cassette, containing a neor gene (PMC1neopA,
Stratagene) and the Flpe6 gene (Buchholz et al., 1998) under the control of the ACE
promoter (Howard et al., 1993) was cloned and placed into the second intron of the
Nemo gene (Figure 2). This cassette was originally designed and cloned in order to
excise itself in the male germline, analogous to the gene self-excision method by
Bunting et al. (Bunting et al., 1999). Unfortunately, it was later found that a two Bp
deletion in the Flpe6 coding sequence rendered the FLPE nonfunctional and the
cassette had to be deleted in vitro by transient expression of Flpe6. A 2.0 kb XmnI-
BglII fragment was used as 5’ homology region, a 2.0 kb BglII-SpeI fragment was
placed between the two loxP sites and a 5.5 kb SpeI-ClaI fragment was used as 3’
homology region. A thymidine kinase gene was used for negative selection of clones
with random integration of the targeting vector. Bruce-4 ES cells (Kontgen et al.,
1993) derived from C57Bl/6 mice, were transfected, cultured and selected as previously
described (Pasparakis and Kollias, 1995; Torres and Kuehn, 1997). Out of 398 G418
and gancyclovir resistant colonies 6 were identified as homologous recombinants with
cointegration of the second loxP site (FN) by Southern blot analysis of BamHI digested
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DNA, using an AccI-XmnI 480 bp fragment as 5’ external probe (probe A) (Figures 2
and 3A). Two NemoFN/Y ES cell clones were then transiently cotransfected with either
Flpe6 and puromycin, or Flpe6, Cre and puromycin encoding plasmids (pFlep6,
pPgkcre and pPgkpuro in a ratio of 1:1:10) to generate ES cells lacking the neor
cassette and/or NEMO coding exon II (genotypes F, DN and D, see Figures 2 and 3A).
Experimental procedures were essentially as described (Pasparakis and Kollias, 1995;
Torres and Kuehn, 1997), except that puromycin selection (1 m g/ml) was applied
between 24-72 hours after transfection. ES cell clones containing neor deletion (F),
exon II deletion (DN) or neor and exon II deletions (D) were identified by Southern blot
analysis of BamHI digested DNA using probe B (600 bp SpHI-EcoRI fragment)
(Figures 2 and 3A). Chimeric mice were generated by injection of NemoFN/Y, NemoF/Y
and NemoD/Y ES cells into blastocysts from CB20 or Balb/C mice. Matings of male
chimeras to C57BL/6 females yielded germline transmitted female offspring of pure
C57BL/6 genetic background in all three cases. NemoD/WT mice were generated by
crossing either chimeras transmitting the NemoFN genotype with Cre-deleter (Schwenk
et al., 1995) yielding NemoDN/WT females or by crossing chimeras transmitting the
NemoD/Y genotype to wild-type C57BL/6 females, yielding nemoD/WT heterozygous
females. Since nemoDN and nemoD are similarly nemo-knockout alleles and no
difference could be detected between the two both NemoDN/WT and NemoD/WT are
referred to as NemoD/WT. NEMO-deficient embryos were generated by crossing
NemoD/WT mice to chimeras transmitting the NemoD genotype. DNA was analyzed by
Southern blot analysis as described above, or by PCR, using 4 primers in one reaction:
27, 39, 40 and 61 (Figures 3A and B). RT-PCR analysis of RNA and Western blot
analysis of extracts from Ne o deleted ES cell clones revealed the presence of a
shortened mRNA and absence of NEMO protein (not shown). Evidence that targeting
of the Nemo genomic locus did not interfere with expression of the neighboring G6pd
gene was obtained by RT-PCR (not shown) and Western analysis (Figure 3C).
Chimeric mice were generated using either NemoFN/Y or NemoD/Y ES cell clones.
Chimeras generated from Ne oD/Y ES cells developed skin lesions 5 to 9 days after
birth. The lesions seemed to be restricted to the ES cell derived black colored skin
areas. The most severely affected animals died at this stage, whereas some chimeras
recovered with complete disappearance of the skin phenotype. Chimeras generated
from NemoFN/Y cells developed normally.
Figure 3. Generation of Nemo knockout Mice II
(A) Southern blot analysis of BamHI digested genomic DNA from ES cell
clones, mice and embryos. Left panel: DNA from parental (WT/Y) and targeted
ES cells carrying the genotypes FN/Y, F/Y, DN/Y and D/Y. Right Panel: DNA
from wild type (WT/WT), heterozygous FN (WT/FN), homozygous FN
(FN/FN) and heterozygous deleted (WT/DN and WT/D) mice, and from
hemizygous DN (DN/Y) and homozygous (D/DN) deleted embryos.
(B) Genotyping of genomic DNA from the above described ES cells, mice and
embryos by PCR using primers 27, 39, 40 and 61.
(C) Western blot analysis of NEMO and G6PD protein expression in






















































































3.2 Analysis of Nemo-knockout Mice
3.2.1 Liver Degeneration in NEMO-deficient Embryos
NEMO-deficient embryos were generated by crossing heterozygous knockout
(NemoDN/WT) females with male chimeras generated from Nemo-deleted (NemoD/Y) ES
cells. Examination of E12.5 NEMO-deficient embryos by TUNEL-assay revealed
degeneration of the liver due to massive apoptosis of hepatocytes. Heterozygous Nemo
knockout embryos also showed increased hepatocyte apoptosis when compared to wild
type embryos (data obtained in collaboration with Dr. Bloch, not shown).
3.2.2 NEMO is Essential for NF- B Activation
Western blot analysis showed complete absence of NEMO protein in MEFs isolated
from E12.5 NEMO-deficient embryos (Figure 3C). To assess the role of NEMO in the
induction of NF- k B we measured NF-k B activation by various means. In order to
directly compare the inhibitory effect of NEMO-deficiency to that of IKK2-deficiency
on the activation of NF-k B by proinflammatory stimuli, we included ikk2 knockout
MEFs (Pasparakis et al., 2002a) into the analysis. Stimulation of the cells by TNF, IL-1
or LPS failed to induce any detectable NF-k B DNA binding activity in NEMO-
deficient MEFs (Figure 4A), although the p65 and p50 NF- k B subunits are expressed at
normal levels in these cells (not shown). In IKK2-deficient MEFs TNF and IL-1, but
not LPS, induced NF- k B DNA binding activity, although the levels of induction were
strongly reduced compared to wild type MEFs. Analysis of Ik B a  protein levels in
cytoplasmic extracts yielded corresponding results (Figure 4A).
Inhibition of NF-k B activity has been shown to sensitize cells to TNF induced
apoptosis (reviewed in (Barkett and Gilmore, 1999)). As shown in Figure 4B, NEMO-
deficient MEFs are extremely sensitive to TNF cytotoxicity even in the absence of
cycloheximide. Addition of the protein-synthesis inhibitor cycloheximide renders cells
more sensitive to apoptosis, since it blocks de novo synthesis of new anti-apoptotic
proteins. Under the same conditions, Ikk2D/D cells show twofold increased viability
compared to NEMO-deficient cells. To examine the role of NEMO in the expression of
NF- k B-dependent genes we measured the production of IL-6 and TNF in these cells.
NEMO-deficient cells failed to produce detectable amounts of IL-6 upon stimulation

















































































































































Figure 4. Comparison of NF- B activation in wild type, NEMO-deficient and
IKK2-deficient MEFs.
(A) Nuclear translocation of NF- k B was demonstrated by electromobility shift assay
and degradation of I k Ba  was analyzed by Western blot. MEFs were incubated with
murine recombinant TNF (10 ng/ml) or IL-1 b  (10 ng/ml) for 15 min and with LPS
(1 m g/ml) for 45 min.
(B) Sensitivity to TNF induced cytotoxicity. MEFs were left untreated (resting) or
stimulated with 10 ng/ml TNF in the absence or presence of 300 ng/ml cycloheximide
(CHX) for 20 h. The amount of cell death was determined by measurement of LDH
activity using a commercially available kit (Promega). Mean and standard deviation
of triplicate samples are shown as the percentage of dead cells relative to the total cell
number for each condition.
(C) Production of cytokines induced by proinflammatory stimuli. MEFs were treated
for 16 h with various stimuli in the indicated concentrations. Levels of IL-6 and TNF
in cell culture supernatants were determined by ELISA. Results are shown as the
mean and standard deviation of triplicate samples.
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compared to wild type cells (Figure 4C). Both NEMO- and IKK2-deficient MEFs did
not release detectable amounts of TNF in response to LPS (Figure 4C). These results
show that NEMO is essential for the induction of NF-k B by proinflammatory signals,
while in the absence of IKK2 residual NF-k B activation still occurs, probably mediated
by IKK1.
3.2.3 NEMO-deficient Mice Model Incontinentia Pigmenti
Heterozygous Nemo-knockout Female Mice Develop Skin Lesions
Heterozygous Nemo knockout mice (NemoD/WT) developed a striking skin defect that
became visible 3 to 4 days after birth, when mice start to develop skin pigment. At that
time point the skin showed areas of reduced or absent pigmentation in a pattern similar
to that seen in chimeric mice (Figure 5A). The extent to which the skin is affected
varies between different mice, probably reflecting the random pattern of X-inactivation.
6 to 7 days after birth the skin of the NemoD/WT mice becomes hard and inflexible,
displaying areas of defective hair growth and extreme scaling. From the appearance of
the skin lesions on, NemoD/WT mice are increasingly growth-retarded and look runted
(Figure 5B). Most of the animals die 6 to 10 days after birth. From 33 NemoD/WT
females born from these initial matings, 29 (88%) died within this time interval: 5 at
day 6, 12 at day 7, 6 at day 8, 4 at day 9 and 1 at day 10. The 4 (12 %) surviving mice
gradually recovered and the scaling skin areas disappeared progressively, leaving
behind some patches lacking hair growth (Figure 5C). After completion of the
histological analyses these matings were stopped to prevent unnecessary suffering of
the mice.
Histopathology of the Skin in Heterozygous Nemo-knockout Mice
In normal skin, keratinocytes proliferate in the basal layer of the epidermis and move
outwards to the suprabasal layers where they progressively accumulate keratin and
finally die as fully differentiated keratinocytes when they reach the cornified layer
(Fuchs, 1993). Microscopic examination of skin sections from 4 and 8 days old
NemoD/WT mice revealed an altered skin structure with a dramatic increase in the
thickness of both the suprabasal and the cornified layer of the epidermis (Figures 6Ad
and Ae), compared to the skin of littermate controls (Figures 6Aa and Ab). At 6 weeks









Figure 5. Heterozygous nemoD/WT female mice develop a disease of
the skin similar to human IP
(A) 4 days old nemoD/WT female and wild type male littermate.
(B) 8 days old nemoD/WT female and wild type male littermate. This
picture shows an extreme case of the runting and wasting seen in
nemoD/WT females.
(C) 5 week old surviving nemoD/WT female mouse. A stripe of the skin





 6Ac) and only small patches are affected, displaying similar, albeit less severe,
histological alterations as the skin of 4 and 8 day old mice (Figure 6Af). In wild type
skin dead keratinocytes composing the cornified layer lack nuclei or cellular organelles
(Figures 6Aa and Ab). In contrast, recognizable cell bodies with nuclei are observed in
the cornified layer of the epidermis from NemoD/WT mice (Figure 6Ad and Ae),
indicating that in these animals keratinocytes that are not fully differentiated reach the
cornified layer.
In sections from affected skin areas in NemoD/WT mice, abnormal gaps form between
keratinocytes of the basal and suprabasal layers (Figures 6Ad-f). To further investigate
this phenomenon electron microscopy was used. As can be seen in Figure 6 Ag, the
cells in the basal layer of normal epidermis are tightly packed. In contrast, in affected
skin areas of NemoD/WT mice basal layer keratinocytes appear to be in loose contact
with each other, forming filopodia that extend into the dilated intercellular spaces
(Figures 6Ah-i). In addition, alterations in tonofilaments and in desmosomal contacts
were observed in keratinocytes in the epidermis of NemoD/WT mice (not shown).
Dyskeratotic cells showing abnormal tonofilament structure and absence of
desmosomes were also observed in the skin of human IP patients (Schamburg-Lever
and Lever, 1973).
Granulocyte Infiltration in the Epidermis and Melanin Deposits in the Dermis are
Common Features in nemoD/WT Mice and Human IP Patients.
A prominent feature of IP at stage I is the presence of massive inflammatory infiltrates
in the epidermis (Landy and Donnai, 1993). Histological examination of sections from
the skin of 4 days old NemoD/WT mice reveals the presence of numerous inflammatory
foci with pronounced infiltration of granulocytes into the epidermis (Figure 6Ba). Only
a few areas showing granulocyte infiltration can be detected in the epidermis of 8 days
old NemoD/WT mice (not shown), indicating that at that age the initial inflammatory
stage is declining.
One of the best described features of IP is the presence of hyperpigmentation (Landy
and Donnai, 1993). Several studies showed that hyperpigmentation is caused by the
presence of increased number of phagocytes containing melanosome complexes in the
dermis (Schamburg-Lever and Lever, 1973; Zillikens et al., 1991). Histological
























Figure 6. Histopathology of the epidermis in NemoD/WT mice.
(A) Skin structure in NemoD/WT (c-f, h, i) and wild type mice (a, b, g) was examined
by light microscopy on 0.5 µm sections stained with methylene blue (a-f) or by
electron microscopy on 60 nm slices (g-i). Increased thickness of the epidermis and
widening of intercellular spaces between keratinocytes are apparent in the skin from
4 days (d) and 8 days (e) old NemoD/WT mice compared to controls (a and b
respectively). In addition, the cornified layer (indicated by an asterisk) is thickened
and shows abnormal structure with recognizable cell fragments (d, e). Sections from
unaffected skin areas of a 6 week old NemoD/WT mouse show normal structure (c),
while in affected areas the epidermis is thickened (f). Basal layer keratinocytes in the
skin from 8 days old NemoD/WT mice are in loose contact with each other with
filopodia (arrows) extending into the intercellular spaces (h, i), in contrast to the tight
adherence observed between basal keratinocytes in skin sections from control mice
(g). BL, basal layer. Bars = 35µm (A-F); 3.5µm (g and h); 2µm (i).
(B) Granulocyte infiltration and hyperpigmentation in the skin of NemoD/WT mice.
(a) Methylene blue stained skin sections from 4 days old NemoD/WT mice show
clusters of infiltrating cells, mainly granulocytes (arrowheads) into the epidermis.
(b) Depositions of melanin granulas (arrows) in the dermis are observed in skin
sections from 6 week old mice (Giemsa staining).
(c) Similar melanin depositions are seen in sections from hyperpigmented skin areas
from stage III IP patients (hematoxylin-eosin-safran staining). Slides from IP patients
were obtained from Christine Bodermer and Sylvie Fraitag.
Bars = 35µm (a); 50µm (b and c)
(C) Increased proliferation and apoptosis in the epidermis of NemoD/WT mice.
(a-d) Detection of proliferating cells in skin sections stained with an antibody to Ki-
67. In the epidermis of 8 days old control mice (a) and in unaffected areas from 6
week old NemoD/WT mice (c) only a few cells in the basal layer proliferate (arrows).
In contrast, nearly all of the basal and many suprabasal keratinocytes proliferate in
the epidermis from affected skin areas in 8 days old (b) and 6 week old (d) NemoD/WT
mice. Arrows indicate Ki-67 positive cells.
(e-f) Immunohistochemical detection of apoptotic cells by staining with antibodies to
the 85 kD fragment of PARP. In sections from 8 days old wild type mice (e) and
from normal skin areas of 6 week old NemoD/WT mice (g), apoptotic cells are
detected only at the border between the suprabasal and the cornified layers
(arrowheads). In contrast, increased apoptosis is detected in suprabasal keratinocytes
in affected skin areas from 8 days old and 6 week old NemoD/WT mice (f, h). In the
epidermis of affected skin areas from 6 week old NemoD/WT mice apoptotic cells are
also detected in the basal layer (h). BL, basal layer; SL, suprabasal layer; CL,
cornified layer. Bars = 40 µm (a-d); 30 µm (e-h).
Histology was performed in collaboration with Dr. Wilhelm Bloch.
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containing melanin in the dermis (Figure 6Bc). A similar picture is observed in sections
from affected skin patches from a 6 week old NemoD/WT mouse (Figure 6Bb).
Increased Proliferation and Apoptosis in the Epidermis of Heterozygous Nemo-
knockout Mice.
Epidermal homeostasis is based on a steady state between proliferation of cells in the
basal layer and apoptosis of terminally differentiated keratinocytes at the border
between the suprabasal and cornified layers (Fuchs, 1993). To determine whether the
epidermal hyperplasia observed in the skin of NemoD/WT mice is caused by increased
proliferation of keratinocytes, we stained skin sections from NemoD/WT and wild type
mice with an antibody to Ki-67, an antigen expressed in proliferating cells. In contrast
to wild type skin where only some cells of the basal layer are Ki-67 positive (Figure
6Ca), nearly all of the basal and many suprabasal keratinocytes are labeled for Ki-67 in
the skin of 8 days old NemoD/WT mice (Figure 6Cb). A similar picture is observed in
affected skin patches at the age of 6 weeks (Figure 6Cd), while in skin areas of these
mice showing normal morphology, only some cells of the basal layer expose Ki-67
(Figure 6Cc).
Staining with antibodies to the 85 kDa fragment of poly-(A)DP-ribose polymerase
(PARP) reveals the presence of apoptotic cells selectively at the border between the
suprabasal and cornified layers of the epidermis in wild type mice (Figure 6Ce) and in
unaffected areas from a 6 week old NemoD/WT mouse (Figure 6Bg). In contrast,
apoptotic cells are detected also in the suprabasal layers in affected areas of 8 days old
NemoD/WT mouse skin (Figure 6Cf). At 6 weeks of age, this pattern of increased
apoptosis is extended to both basal and suprabasal keratinocyte layers, but is detected
only in small affected patches showing abnormal structure and increased proliferation
(Figure 6Ch). It seems therefore that a combined increase of proliferation and apoptosis
of keratinocytes contributes to the skin phenotype observed in NemoD/WT mice.
3.2.4 Lack of NEMO-deficient Lymphocytes in Chimeras Generated with Nemo-
knockout ES Cells
One of the consistent features of IP is the complete skewing of X inactivation in blood





CD3 +   Cell No
H - 2kb
NemoD/Y Chimera NemoFN/Y Chimera
Figure 7. Absence of ES cell derived lymphocytes in chimeras generated with
NEMO-deficient ES cells.
Flow cytometric analysis of PBL from chimeras generated from floxed (nemoFN/Y)
or NEMO-deficient (nemoD/Y) ES cells. Cells were stained with anti-CD45R/B220,
anti-CD3e , anti-H2-kd and anti-H2-kb monoclonal antibodies. Host derived
lymphocytes are H2-kd positive and ES cell derived lymphocytes are H2-kb
positive. (A) Histograms showing H2-kb expression levels of B220+ (B cells) and
CD3+ (T cells) gated lymphocyte populations. (B) Dot plot showing H2-kb and H2-
kd staining of total PBL. Results are representative of 5 chimeras per genotype.
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carrying either a deleted (nemoD/Y) or a floxed (nemoFN/Y) nemo allele, to test whether a
similar skewing occurs against lymphocytes derived from the NEMO-deficient ES
cells. X inactivation in the mouse embryo starts after 4.5 days post coitum (d.p.c.) (Tan
et al., 1993), while ES cells are injected into blastocysts at 3.5 d.p.c. Thus chimerism
can be considered as a simulation of lyonization in females. This is further supported
by the observation that male chimeras obtained from NemoD/Y ES cells displayed a skin
phenotype similar to that seen in NemoD/WT female mice.
The targeted ES cells are derived from C57BL/6 mice and were injected into CB20 or
Balb/c blastocysts. Thus host and ES cell derived lymphocytes can be distinguished by
haplotype-specific staining for Class I MHC molecules, since C57BL/6 mice express
the H-2b and CB20 and Balb/c mice the H-2d haplotype. Flow cytometric analysis of
PBL from chimeras generated from ES cells containing a floxed nemo allele
(nemoFN/Y), reveals the presence of both ES cell and host derived B and T lymphocytes
(Figure 7A and B). ES cell derived B and T cells were not detected in chimeras
generated from Nemo knockout (NemoD/Y) ES cells, although normal numbers of B and
T cells derived from the host blastocyst were present (Figure 7A and B), indicating that
NEMO-deficient lymphocytes either do not develop or are counter-selected in these
chimeras.
3.3 Analysis of a Kinase-dead Mutant of IKK2
In the absence of IKK2 IKK complexes consist of NEMO associated with IKK1
homodimers and exhibit inducible kinase activity (Li et al., 2000; Rothwarf and Karin,
1999). To eliminate IKK2 kinase activity without disrupting IKK stoichiometry another
conditional ikk2 allele, allowing replacement of IKK2 by a kinase-dead molecule
(IKK2 D K) upon Cre-expression, was generated by Manolis Pasparakis (Pasparakis et
al., 2002b). This allele (ikk2 KFL) was produced by placing only exon 7 of the Ikk2
gene between lox P sites. After deletion of exon 7, exons 6 and 8 splice in frame and
the resulting mRNA should produce a truncated IKK2 protein lacking amino acids 160-
189, which include the two serines of the activation loop (Ser177, 181) that are essential











Figure 8. The conditional ikk2 K allele. Schematic representation of the wild-type
(WT) ikk2 allele, which producesWT IKK2 protein and the ikk2 K allele, which
after deletion of loxP-flanked exon 7 ge erates a kinase-dead v rsion of IKK2
(IKK2D K). Open and filled boxes represent exons, triangles represent loxP sites
and the two serines of the IKK2 activation loop are indicated using the amino acid
single letter code.
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I conducted the biochemical analysis of MEFs generated from Ikk2 KD/WT and
Ikk2 KD/D embryos and compared them to Ikk2D/WT, Ikk2D/D and WT MEFs. The
ikk2 KD allele produces a protein that is recognized by antibodies raised against IKK2,
which has a slightly lower molecular weight (Figure 9A). The level of the IKK2D K
protein in Ikk2 KD/D MEFs is lower than that of IKK2 in WT MEFs (Figure 9A). This
could be due to either decreased expression or increased degradation/instability of
IKK2 D K. IKK2 D K is integrated into the IKK complex, as shown by
immunopricipitation with antibodies raised against NEMO. Subsequent Western
blotting showed that NEMO interacts with IKK2D K and IKK1 in Ikk2 KD/D MEFs
(Figure 9B). Kinase-dead IKK2 can act as a dominant negative protein (Delhase et al.,
1999). In Ikk2 KD/WT MEFs, heterozygous expression of IKK2 D K did not reduce NF-
k B activation in response to LPS or TNF compared to heterozygous IKK2 knockout or
WT MEFs. This could be due to the low level of IKK2 D K protein. In Ikk2 KD/D MEFs
LPS induced activation of NF-k B all but abolished, as in IKK2 knockout MEFs
(Figures 9C and 4A). In response to 20 min TNF treatment a residual activation of
similar magnitude could be observed in both IKK2 mutant MEFs (Figure 9C).
Subsequently a detailed time-course analysis of the NF-k B response to IL-1 or TNF
treatment was undertaken, comparing WT, NEMO deficient, IKK2 deficient and
Ikk2 KD/D MEFs (Figures 10A and B). No significant difference in NF- k B DNA
binding monitored by EMSA or Ik B-a  degradation could be detected between Ikk2-
knockout and Ikk2 KD/D MEFs. Subsequently, the activation of NF-k B-dependent
genes in WT, Nemo-knockout, Ikk2-knockout and Ikk2 KD/D MEFs was tested by
measuring two different parameters that are known to depend on NF- k B acivity: TNF-
mediated cytotoxicity (Barkett and Gilmore, 1999) (Figure 11A) and production of IL-
6 in response to proinflammatory stimuli (Figure 11B). WT MEFs are resistant whereas
NEMO-deficient MEFs are extremely sensitive to TNF-induced apoptosis (Makris et
al., 2000; Rudolph et al., 2000; Schmidt-Supprian et al., 2000), since they fail to
express NF- k B-dependent anti-apoptotic proteins. In this setting, Ikk2 KD/D MEFs are
more sensitive to TNF-induced apoptosis than Ikk2D/D MEFs (Figure 11A). Similarly
the production of IL-6 in response to IL-1, LPS or TNF is reduced in Ikk2 KD/D MEFs












































































































Figure  9 .  Analys i s  o f  Ikk2 KD/D M E F s  expressing
IKK2 K instead of IKK2 compared to IKK2-deficient
and WT MEFs.
(A) Western blotting demonstrated that the ikk2 KD/D allele
expresses a kinase-dead protein (IKK2D K) lacking the
activation loop, but at a much lower level than WT IKK2.
Ikk2 KD/D express the same amount of IKK1 and I k B-a  as
Ikk2D/D and WT MEFs.
(B) IKK2D K interacts with NEMO. Western Blotting for
IKK1 and 2 after immunoprecipitation using Abs against
NEMO revealed that in Ikk2 KD/D MEFs NEMO interacts
with IKK2D K as well as with IKK1.
(C) Electromobility shift analysis of NF-k B activation in
WT, Ikk2 KD/WT, Ikk2 KD/D, Ikk2D/WT and Ikk2D/D MEFs in
response to LPS and TNF.
AFigure 10. Time course analysis in NF- B activation in wild type, NEMO-
deficient, IKK2-deficient and IKK2 K-expressing MEFs.
(A) MEFs were stimulated with IL-1 b  (10 ng/ml) for the indicated time-periods
before preparation of nuclear and cytosolic extracts. Nuclear translocation of
NF-k B was demonstrated by electromobility shift assay. IL-1b  induced
degradation of Ik Ba  was analyzed by Western blot. The blot was reprobed
with Abs to SHP-2 as a loading control.
(B) MEFs were stimulated with TNF (10 ng/ml) for the indicated time-periods.
Nuclear translocation of NF-k B was demonstrated by electromobility shift

















































































































































































































Resting IL-1 TNF LPS
Figure 11. Comparison of TNF-induced Cell death and IL-6 production in
wild type, NEMO-deficient, IKK2-deficient and IKK2-kinase dead MEFs.
(A) Sensitivity to TNF induced cytotoxicity. MEFs were left untreated (resting) or
stimulated with 10 ng/ml TNF in the absence or presence of 300 ng/ml
cycloheximide (CHX) for 20 h. The amount of cell death was determined by
measurement of LDH activity using a commercially available kit (Promega). Mean
and standard deviation of triplicate samples are shown as the percentage of dead
cells relative to the total cell number for each condition.
(B) Production of cytokines induced by proinflammatory stimuli. MEFs were
treated for 16 h with various stimuli in the indicated concentrations. Levels of IL-6
in cell culture supernatants were determined by ELISA. Results are shown as the




deficient MEFs (Figure 11B). These results indicate that NF-k B activation is more
impaired in Ikk2 KD/D MEFs than in IKK2 knockout MEFs, although inhibition is not
as complete as in NEMO deficient MEFs.
3.4 The IKK Complex is Essential for B Cell Maintenance
To delete the loxP flanked nemo and ikk2 alleles in B lymphocytes we used a
transgenic mouse strain expressing Cre recombinase under the control of the
endogenous CD19 locus (Rickert et al., 1997). This CD19-Cre mouse has been shown
to delete loxP flanked alleles specifically in the B cell lineage. The deletion efficiency
was shown to be 75-80% in bone marrow and over 95% in splenic B cells (Cazac and
Roes, 2000; Inui et al., 2002; Rickert et al., 1997) (Figure 12). The fact that deletion
efficiency is higher in splenic than in bone marrow B cells indicates that Cre-mediated
deletion is an ongoing process during B cell development and maturation, leading to
the essentially complete deletion of loxP flanked alleles in mature B cells.
3.4.1 Flow Cytometric Analysis of the B Cell Compartment in CD19-Cre/Ikk2FL/D,
-Ikk2 KFL/D and -NemoFL/Y  Mice
Initial FACS analysis of B cell populations in Ikk2FL/FL, Ikk2FL/D, Ikk2 KFL/FL,
Ikk2 KFL/D and NemoFL/Y mice did not show any differences compared to controls. In
order to facilitate Cre-mediated deletion, I used mice in which only one loxP flanked
allele remains to be deleted (CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D and -NemoFL/Y) for my
experiments. FACS analysis of B cell populations in these mouse strains revealed very
similar pictures. In the bone marrow early B cell development was essentially normal
and the only difference found compared to control mice was a 2-4 fold reduction of
mature recirculating B cells (Figure 13A and B). In the spleen the percentage of B cells
was strongly reduced, leading to an inverted B/T cell ratio (Figures 14A and B). The
reduction seems to occur mainly in the IgMlowIgD+ mature B cell population. Splenic B
cells were then subdivided into immature (IM -CD21lowHSAhigh), follicular (FO -
CD21intHSAlow) and marginal zone (MZ - CD21highHSAint) B cells according to CD21
and HSA expression (Allman et al., 1993; Bigos et al., 1999) (Figure 12). This analysis




































Figure 13. FACS analysis of bone marrow B cell populations.
(A) CD19-Cre/Ikk2FL/D,  Ikk2 KFL/D and  con t ro l s  and (B) CD19-
Cre/NemoFL/Y and control mice. Genotypes are as indicated. Cell surface
markers are shown as coordinates and gated cell populations are indicated
in brackets. The numbers next to boxed lymphocyte populations refer to the




























































CD19-CreFigure  14. FACS
analysis of splenic B cell
populations.
(A) CD19-Cre/Ikk2FL/D,






markers  a re  shown as
coordinates and gated cell
populations are indicated
in brackets. The numbers
next to boxed lymphocyte
populations refer to the
percentages of live cells in
the lymphocyte gate.
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revealed  that, compared to controls, the FO B cells are the most diminished B cell
population in the spleens of CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D and NemoFL/Y mice
(Figure 14A and B). Lymph node B cells and both B1 and B2 cells in the peritoneal
cavity of these mice were also strongly reduced compared to control mice (data not
shown).
3.4.2 Reduction of Absolute B Cell Numbers in Mice with B cell Specific Ablation
of NEMO or IKK2
FACS analysis showed a strong reduction of mature B cells in mice with B-cell specific
ablation of NEMO or IKK2. Calculation of the absolute cell numbers of individual B
cell populations in the spleens of CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D and -NemoFL/Y mice
revealed a 3-4 fold decrease in the total number of splenic B cells in all mutant mouse
strains compared to controls (Figure 15A and Table 6). FO and MZ B cells were most
severely affected (Figure 15C and D and Table 6). Analysis of IM B cells revealed a
different picture in the three different mouse-strains. This population was not
significantly affected in CD19-Cre/Ikk2FL/D mice, while a clear reduction was observed
in CD19-Cre/NemoFL/Y mice and CD19-Cre/Ikk2 KFL/D mice showed an intermediate





Ikk K2FL/FL or FL/D
CD19-Cre
NemoFL/Y or FL/FL
        Total  42.0 ± 11.2 12.8 ± 1.1 9.9 ± 4.3 11.9 ± 1.7
           IM  6.1 ± 1.6  5.0 ± 1.0 2.9 ± 1.0  1.8 ± 0.5
           FO 27.3 ± 9.1  5.5 ± 0.5 3.7 ± 2.0  8.5 ± 1.5
          MZ  3.9 ± 1.4  0.9 ± 0.2 2.4 ± 1.1  1.1 ± 0.3
Table 6. Size of B cell subsets in CD19-Cre/IKK-conditional mice compared to
control mice
The average of absolute numbers of live B cells is shown in millions plus/minus
standard deviation (CD19-Cre/Ikk2FL/D or FL/FL: n = 3; CD19-Cre/Ikk K2FL/FL or FL/D: n =






Cells [Mio] 6.1 5 2.9 1.8








Cells [Mio] 42 12.8 9.9 11.9
WT IKK2 KO IKK2 DK NEMO KO
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Cells [Mio] 27.3 5.5 3.7 8.5
WT IKK2 KO IKK2 DK NEMO KO
Follicular B Cell Numbers Marginal Zone B Cell NumbersC D
Figure 15. Reduction of B cell numbers in CD19Cre/IKK-conditional mice.
Absolute numbers of B cell subpopulations in the spleens of CD19-Cre/Ikk2FL/D,
CD19-Cre/Ikk2 KFL/D and CD19-Cre/NemoFL/Y compared to control mice are
shown. (A) Total B cell numbers (B) Immature B cells (C) Follicular B cells (D)
Marginal Zone B cells. Bar charts showing the absolute c ll numbers for the
indicated B cell population in the spleen for each of the following mouse strains:
CT (controls), IKK2 KO (CD19-Cre/Ikk2FL/D), IKK2 DK (CD19-Cre/Ikk2 KFL/D)
and NEMO KO (CD19-Cre/NemoFL/Y). For each group three to eight mice were
analyzed. Error bars indicate standard deviation. The absolute cell numbers for
each population were calculated by multiplying the percentage of each B cell
subset of all live splenocytes obtained from the FACS analysis with the total
number of live cells recovered from the perspective spleen.
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3.4.3 Preferential Loss of Splenic B Cells of the Deleted Genotype in CD19-
Cre/Ikk2FL/D, -Ikk2 KFL/D and -NemoFL/Y Mice
The strong decrease of peripheral B cell numbers in mice with B cell specific ablation
of NEMO or IKK2 activity suggests that inhibition of IKK signaling interferes with the
development or persistence of B lymphocytes. However, all different subpopulations of
B cells are present in CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D and -NemoFL/Y mice, although in
reduced numbers. One possible explanation for this could be that the remaining cells
persist because they have escaped deletion of the loxP flanked alleles.
To investigate this hypothesis I performed Southern blot analysis of DNA isolated from
FACS-purified BM and splenic B cells populations from these three strains of mice.
This analysis revealed that between 64-76% of bone marrow IgM- B cells had deleted
the loxP-flanked alleles (Figure 16A-C). This result is in agreement with the previously
reported deletion efficiency of the CD19-Cre transgene in the bone marrow (Rickert et
al., 1997) and with deletion seen in CD19-Cre/Ikk2FL/WT mice, in which deletion of the
loxP-flanked allele has no effect due to IKK2-expression from the remaining WT allele
(Figure 16D). Between 64 - 69% of the IgM+ bone marrow B cells isolated from CD19-
Cre/Ikk2FL/D, -Ikk2 KFL/D and -NemoFL/Y mice have deleted the loxP-flanked allele,
compared to an 87% deletion of the loxP-flanked allele in CD19-Cre/Ikk2FL/WT mice.
This indicates that IKK-deleted IgM+ bone marrow B cells are counterselected, in
accordance with the reduced number of recirculating B cells in the bone marrow of
these mice. While deletion was very efficient in splenic IM CD19-Cre/Ikk2FL/D and -
Ikk2 KFL/D B cells (>90%), only 44-66% of FO B cells were found to have deleted the
loxP flanked alleles (Figure 16 A and B). In CD19-Cre/Ikk2FL/WT mice deletion was
87% and 95% for IM and FO B cells, respectively (Figure 16D). The finding that
within the follicular B cell compartment there are less cells of the deleted genotype
than in the immature compartment suggests that B cells lacking IKK2 activity are
counter-selected as they move on to become more mature FO B cells (Figure 16A and
B). In CD19-Cre/NemoFL/Y mice deletion in IM splenic B cells was less efficient than in
the IKK2 loxP flanked alleles ( » 70% compared to >90%) and was not further reduced
in FO B cells (Figure 16C). This indicates that the cells that delete the nemoFL allele are
already counter-selected at the immature B cell stage. A more dramatic effect is seen in
MZ B cells. In all three mouse strains very few cells with deleted alleles (£ 12%) were
found within the marginal zone B cell population, whereas in CD19-Cre/Ikk2FL/WT mice
T IgM- IgM+ IM FO MZ
Del (%): 51 82 82 96 83 56
Ikk2 KD/D Cells (%)








T IgM- IgM+ IM FO MZ















Del (%): 0 62 87 87 95 99
Ikk2WT/D Cells (%)
D
T IgM- IgM+ IM FO MZ
Del (%): 50 84 83 96 72 54
Ikk2D/D Cells (%)








T IgM- IgM+ IM FO MZ
Figure 16. Counterselection against IkkD/D-, Ikk2 KD/D and NemoD/Y B cells in
the spleen. Southern blot analyses of sorted splenic B cell populations of mice of
the indicated genotypes are shown. (A) CD19-Cre/Ikk2FL/D mice,  (B) CD19-
Cre/Ikk2 KFL/D mice, (C) CD19-Cre/NemoFL/Y mice, (D) CD19-Cre/Ikk2 KFL/WT
mice.  T (Tail),  IgM- (CD19+B220+IgM- = pro-  and pre-B cel ls) ,  IgM+
(CD19+B220+IgM+ B cells), IM (CD19+CD21lowHSAhigh = Immature B cells),
FO(CD19+CD21intHSA- = Follicular B cells), MZ (CD19+CD21highHSAint =
Marginal Zone B cells). The percentage of deleted alleles and cells of the deleted
genotype is given below the blots. Each blot is a representative example of at least
4 mice analyzed. Del(%) = Percent of deleted alleles.
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deletion was virtually complete, suggesting that IKK activity is essential for the
development or maintenance of these cells (Figure 16 A-D).
Based on the above data I envisage the following scenario: Ongoing deletion
continuously leads to the generation of B cells that have deleted the respective gene,
but still retain enough protein to stay alive. With time and through turnover of
endogenous mRNAs and proteins these cells lose their ability to signal via the IKK
complex and die. Continuous influx of newly generated B cells from the BM and
continuous Cre-mediated deletion of the loxP flanked alleles leads to the deletion
pattern observed in B cells of CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D and -NemoFL/Y mice.
This scenario predicts a higher turnover rate of mutant compared to control B cells.
3.4.4 CD19-Cre/Ikk2 KFL/D and CD19-Cre/NemoFL/Y B Cells Have Higher in vivo
Turnover Rates than Wild-type Control B Cells
To test this hypothesis I determined the percentage of BrdU-labeled B cells of the
various B cell subpopulations in BM and spleens of CD19-Cre/NemoFL/Y and control
mice that had been fed with BrdU for one week (Figure 17).  In the BM B220+/IgD-
slightly more CD19-Cre/NemoFL/Y B cells incorporated BrdU then control B cells
(Figure 17A). After one week of BrdU-administration in the drinking water the
proportion of BrdU-labeled splenic B cells is around 10 % (Forster and Rajewsky,
1990). These most likely represent newly formed B cells that arrived recently from the
bone marrow, since peripheral B cells have a long life-span and do not proliferate a lot
(Forster and Rajewsky, 1990; Hao and Rajewsky, 2001). An increase in percentage of
BrdU-positive B cells in the spleen therefore would indicate a higher rate of B cell
renewal in the spleen. Approximately twice as many CD19-Cre/NemoFL/Y BM
recirculating, IM, FO and MZ B cells in the spleen incorporated BrdU compared to
control B cells Figure 17 B). This result shows that B cell turnover in the spleen of
CD19-Cre/NemoFL/Y mice is significantly faster than in wild-type animals. The
percentage of BrdU-positive B cells within each subpopulation reflects the cellular
turnover. The increased B cell turnover in CD19-Cre/NemoFL/Y mice suggests that IKK
mutant splenic B cells have a shorter half-life then control B cells.
Figure 17. Increased B cel l  turnover in CD19-Cre/NemoFL/Y
 
mice
compared to control mice.
Analysis of BrdU incorporation by bone marrow (A) and splenic (B) B cells of
mice of the indicated genotypes after one week of BrdU administration in the
drinking water. Cell surface markers are shown as coordinates and gated cell
populations are indicated in brackets, all populations are gated on live
lymphocytes. Numbers indicate percentages of BrdU-positive B cells of gated
populations. B220+ (bone marrow B cells), IM (CD19+CD21lowHSAhigh =
Immature B cells), FO(CD19+CD21intHSA- = Foll icular B cells), MZ









































3.4.5 Blockade of de novo B Cell Generation in CD19-Cre/Ikk2 KFL/D Mice leads to
Disappearance of IKK2-deficient B Cells from the Spleen.
During B cell development peripheral B cells are continuously generated from the bone
marrow. I decided to evaluate whether CD19-C e/Ikk2 KFL/D B lineage lymphocytes
that underwent Cre-mediated deletion can persist in the spleen by blocking influx of IM
B cells from the bone marrow. This was achieved by injection of antagonistic
monoclonal antibodies against the interleukin-7 receptor (IL-7R). This treatment blocks
B cell development at the pro-B cell stage and thus abolishes the influx of IM B cells
from the bone marrow into the periphery (Sudo et al., 1993).
After four weeks of anti-IL-7R antibody administration FACS analysis demonstrated
that B cell development in the bone marrow and the influx of newly generated B cells
into the spleen is indeed inhibited in antibody-treated mice (Figure 18A). Southern blot
analysis of DNA isolated from purified splenic B cells of these mice revealed the
absence of Ikk2 KD/D B cells (Figure 18C), whereas in untreated CD19-Cre/Ikk2 KFL/D
mice 50 to 80 % of the CD19-positive splenic B cells have exon-deleted both loxP-
flanked ikk2 K alleles (Figure 18B). This finding validates the view that the B cells
with two exon-deleted ikk2 K alleles that are found in the spleens of CD19-
Cre/Ikk2 KFL/D mice are cells that have only recently undergone Cre-mediated
recombination and still retain IKK2 protein. As soon as the influx from the bone
marrow is blocked, no new B cells having freshly acquired the deleted genotype enter
the spleen from the bone marrow. Within a period of 4 weeks all B cells lacking IKK2
activity disappear from the spleen and only cells that have escaped Cre-mediated
deletion of the loxP flanked alleles persist. These results demonstrate that IKK-
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Figure 18. Block of B cell influx from the bone marrow leads to
disappearance of B cells of the deleted genotype in the spleen.
(A) Verification of the block in B cell development after injection of anti IL-
7R Antibodies by FACS analysis. Non-injected control mice are compared to
mice that had received injections of anti IL-7R antibodies for four weeks. The
genotypes are as indicated above and cell surface markers are shown as
coordinates and gated cell populations are indicated in brackets. The numbers
next to boxed lymphocyte populations refer to the percentages of live cells in
the lymphocyte gate.
(B) Southern blot analysis of Cre mediated deletion in total splenic B
cells from two different (#1,#2) CD19-Cre/Ikk2 KFL/D mice. The results
are representative of six different mice.
(C) Southern blot analysis of Cre mediated deletion in total splenic B
cells from three different (#1-3) CD19-Cre/Ikk2 KFL/D mice that received
anti IL-7R Antibody injections for four weeks.
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3.5 The Role of the IKK Complex in Mature T Cell Development
3.5.1 Naive T Cell Survival Does Not Depend on IKK2, but Lack of NEMO is
Incompatible With T Cell Generation and/or Persistence
To investigate the role of IKK signaling in T lymphocytes, I sought to inhibit IKK
activity specifically in T lineage cells by crossing Ikk2FL/FL and NemoFL/Y mice with





NemoFL/Y or FL/FL Controls
              CD8-SP  2.29 ± 0.28  1.28 ± 0.16  2.11 ± 0.42
              CD4-SP  7.67 ± 0.65  6.32 ± 0.53  7.59 ± 0.90
              DP 85.36 ± 1.98 86.41 ± 2.31 85.61 ± 2.13
              DN  2.69 ± 0.56  3.88 ± 2.30  3.43 ± 1.33
CD4-SP/HSAhigh+int 84.08 ± 1.79 91.34 ± 4.16 82.63 ± 2.21
              /HSAlow 16.54 ± 2.14  8.74 ± 4.24 17.41 ± 2.30
  CD8-SP/HSAhigh 17.06 ± 3.89 38.60 ± 7.76 19.54 ± 5.40
               /HSAint 52.01 ± 5.77  54.48 ± 13.03 50.84 ± 5.16
               /HSAlow 30.80 ± 4.20  4.83 ± 2.27 30.11 ± 2.31
    TCRhigh/CD8-SP 15.32 ± 1.62  6.27 ± 1.09 13.39 ± 2.18
                /CD4-SP 62.86 ± 3.90 65.79 ± 4.59 65.42 ± 3.93
                /DP 20.59 ± 5.12 24.62 ± 4.88 20.07 ± 4.85
 Table 7. Percentages of thymocyte subpopulations in CD4-Cre/IKK-conditional
and control mice.
Cell-types, genotypes and the number of mice analyzed per group are indicated. Average
percentages of total thymocytes are shown in bold numbers plus/minus standard
deviations (CD4-Cre/Ikk2FL/D or FL/FL: n = 10; CD4-Cre/NemoFL/Y or FL/FL: n = 7; Controls: n
= 17). Total thymocyte numbers do not vary significantly between the individual groups.
CD4-Cre mice are reported to delete loxP-flanked alleles in the T lineage with very
high efficiency (Lee et al., 2001; Wolfer et al., 2001) (Figure 19). FACS analysis of T
cell populations in CD4-Cre/Ikk2FL/D mice revealed that thymocyte development is
unperturbed (Figure 20 and Table 7).
In the periphery, however, the number of T cells is reduced, the deficit being more
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Figure 19. Sketch of T cell development in the thymus and deletion efficiency
of the CD4-Cre  mouse line
In the thymus T cell development can be visualized by the expression of the
coreceptors CD4 and CD8. Thymocytes pass  from the double-negative (DN)
through  the double-positive (DP) to the respective single-positive (SP) stages.
Then they exit as CD4 and CD8 T cells into the periphery. Deletion of loxP-
flanked alleles by the CD4-Cre transgeneis essentially complete from the DP-
stage on.
Figure 20. FACS analysis of T cell populations in CD4-Cre/Ikk2FL/D mice
compared to control mice.
Genotypes are as indicated. Cell surface markers are shown as coordinates.
The numbers in the quadrants refer to the percentages of this T cell
population of live cells in the lymphocyte gate.
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Cre/NemoFL/Y mice showed a different picture. In the thymus of these mice the
population of CD8 single positive cells is a little more than half the size of that of
control mice while CD4 single positive cells are only mildly reduced (Figure 21 and
Table I).  Spleen and LN of CD4-Cre/NemoFL/Y mice are nearly devoid of mature T
cells (Figure 21). Deletion of floxed alleles by Cre transgenes is not always complete,
especially when cells that have deleted their loxP-flanked alleles are counter-selected
(Pasparakis et al., 2002b; Rajewsky et al., 1996). Therefore I assessed the genotype of
the T cell populations found in the two CD4-Cre/IKK-conditional mouse strains.
Deletion of only one out of two loxP-flanked alleles can cause problems for the
assessment of deletion efficiency by Southern blot. In CD4-Cre/Ikk2FL/FL mice, for
example, it is impossible to determine from a Southern blot to what extent the bands
representing the loxP-flanked and the deleted alleles stem from Ikk2FL/D T cells and to
what extent they stem from Ikk2FL/FL and Ikk2FL/D T cells. In order to avoid
complications caused by this “incomplete” deletion, I used mice in which only one
loxP flanked allele remains to be deleted (CD4-Cre/Ikk2FL/D and -NemoFL/Y) for
monitoring deletion by Southern blot.
Southern blot analysis of DNA prepared from sorted T cell populations from CD4-
Cre/Ikk2FL/D mice shows that in double positive and in single positive thymocytes, and
in CD4 and CD8 T cells in the spleen and lymph nodes deletion of the loxP flanked
allele is essentially complete (Figure 22A). The faint band representing loxP-flanked
alleles that can be observed for CD8 SP thymocytes is most likely due to immature
CD8 SP cells. These cells are immature, large, outer-cortical cells that lack the TCR
complex but express CD8 (Shortman et al., 1988). Maturation of single-positive
thymocytes is normal in CD4-Cre/Ikk2FL/D mice; CD8- and CD4-SP thymocytes have
the same expression profile of HSA (CD24) (Figure 24A and Table). Loss of HSA-
expression can be correlated to increased maturation of single-positive thymocytes.
Similarly the CD4 versus CD8 ratio is normal in TCRhigh thymocytes of CD4-
Cre/Ikk2FL/D mice (Figure 24B and Table). To demonstrate that inactivation of the Ikk2
gene in T cells of these mice leads to T cells lacking IKK2, I analyzed extracts from
thymocytes and peripheral CD4 T cells by western blotting. This analysis showed that
Ikk2D/D thymocytes still contain IKK2 protein (Figure 22B), probably owing to the long
half-life of IKK2 (approximately 13 h in monocytic cell-lines) (Fischer et al., 1999).
This means that even though thymocytes isolated from CD4-Cre/Ikk2FL/D are
genetically Ikk2D/D, they are not IKK2-deficient since they still contain IKK2 protein.
AB
Figure 22. Southern and Western
Analysis of sorted T cell populations
in CD4-Cre/Ikk2F/D and control mice
(A) DNA was prepared from DN, DP,
CD4-SP and CD8-SP thymocytes and
mature CD4 and CD8 Tcells from LN
and spleen, sorted from CD4-
Cre/Ikk2F/D mice. Southern Blot
analysis revealed deletion in each T cell
subset.
(B) Cytosolic extracts were prepared
from thymocytes and splenic CD4 T
cells sorted from CD4-Cre/Ikk2F/D and
Ikk2F/FL and Ikk2F/D control mice.  IKK2
levels in these cells are revealed by
Western blotting. IKK1 levels serve as
loading control.
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Peripheral T cells in these mice are, on the other hand, truly IKK2-deficient, since no
IKK2 protein could be detected in splenic Ikk2D/D CD4 T cells (Figure 22B).
Deletion of the loxP-flanked alleles is complete in DP and CD4-SP thymocytes of
CD4-Cre/NemoFL/Y mice,which carry only one nemoFL allele, similar to CD4-
Cre/Ikk2FL/D mice (Figure 23A). Western Blot analysis showed strong reduction of
NEMO levels in DP and nearly complete absence of NEMO in CD4-SP thymocytes
isolated from CD4-Cre/NemoFL/Y compared to control mice (Figure 23 B and C).
Southern blot analysis of the remaining peripheral T cells of CD4-Cre/NemoFL/Y mice
revealed that in the periphery of CD4-Cre/NemoFL/Y mice virtually all deleted cells have
disappeared. Only a weak band representing cells of the deleted genotype can be
detected in DNA prepared from CD4 T cells (Figure 23A). This shows that the few T
cells that are left in CD4-Cre/NemoFL/Y mice are T cells in which deletion of the loxP-
flanked alleles did not occur. These T cells accumulate in the periphery, whereas T
cells of the deleted genotype cannot persist.
This view is supported by further FACS analysis: in the CD8-SP compartment of CD4-
Cre/NemoFL/Y mice the number of HSA++ immature CD8-SP thymocytes is equal, but
there is a decrease in HSAint cells and there are only very few HSAlow mature cells
(Figure 24A and Table 7). This is paralleled by a reduction in TCRhigh CD8-SP
thymocytes (Table 7). It seems that after deletion of the loxP-flanked alleles the
endogenous IKK2 or NEMO mRNA and protein are gradually lost through turn-over
while the cells mature. Thymocytes and T cells that lack NEMO cannot survive and are
lost. Also the HSAlow CD4-SP compartment is reduced (Table 7), albeit to a lesser
extent. The remaining peripheral T cells in CD4-Cre/NemoFL/Y mice express high levels
of CD44, which is characteristic for T cells that undergo homeostatic expansion in a
lymphopenic environment and become memory-type T cells (data not
shown)(Goldrath, 2002; Goldrath et al., 2000; Surh and Sprent, 2000).
To ascertain that the effects seen in the CD4-Cre/IKK-conditional mice are due to T
cell intrinsic defects I analyzed dendritic cell populations in CD4-Cre/Ikk2FL/D and -
NemoFL/Y mice compared to control mice.  These mice contain normal numbers of
CD11c+CD4+ and CD11c+CD8+ dendritic cells. Southern blot analysis of DNA from
MACS-purified dendritic cells showed that the CD4-Cre transgene does not induce
deletion of ikk2FL or nemoFL alleles in dendritic cells. I also did not detect deletion at





Figure 24. FACS analysis of single-positive thymocyte development in
CD4-Cre/NemoFL/Y and CD4-Cre/Ikk2FL/D mice compared to control mice.
(A) Histogram of CD24 expression on CD8-SP thymocytes. White
histograms show control cells and grey histograms CD4-Cre/Ikk2FL/D or CD4-
Cre/NemoFL/Y , respectively.
(B) Dotblots showing CD4 versus CD8 expression in TCRhigh thymocytes.
Genotypes are as indicated and gated cell populations are indicated in
brackets. Cell surface markers are shown as coordinates. Numbers refer to the
percentage of the respective T cell population of live cells in the lymphocyte






















3.5.2 CD4-Cre/Ikk2FL/D Mice Have Reduced CD25 and CD44 CD4 T Cell
Compartments.
In the spleen and LN of CD4-Cre/Ikk2FL/D mice the CD4 T cell compartment is reduced
by approximately 20% and the CD8 T cell compartment by over 50% compared to
control mice (Figures 25A and B and Table 8).
OrganCell-Type
CD4-Cre
Ikk2FL/D or FL/FL Ikk2FL/D or FL/FL
Spleen CD4 13.93 ± 3.57 17.75 ± 3.93
CD8  5.54 ± 1.94 12.58 ± 3.83
B cells 73.80 ± 5.86  58.17 ± 10.12
LN CD4  7.54 ± 3.57 10.53 ± 3.02
CD8  2.87 ± 1.02  7.70 ± 2.25
B cells 15.06 ± 6.88 10.80 ± 5.67
Table 8. Absolute B and T cell numbers in spleen and lymph nodes
Averages of absolute numbers of live B and T cells are shown in bold
in millions plus/minus standard deviation (CD4-Cre/Ikk2FL/D or FL/FL: n =
11; Ikk2FL/D or FL/FL: n = 11).
In normal mice around 10 % of the CD4 T cells co-express the interleukin-2 receptor
(IL-2R; CD25) a -chain (Asano et al., 1996). These CD4+CD25+ T cells are suggested
to be generated in the thymus and it has been shown, by various in vitro and in vivo
experiments, that they downregulate immune responses and inhibit development of
autoimmune diseases (for recent reviews see (Curotto de Lafaille and Lafaille, 2002;
Read and Powrie, 2001; Shevach, 2001; Shevach, 2002); they are therefore termed
suppressor or regulatory T cells. T cell populations with immuno-suppressive
properties have also been found within the CD4/CD25- T cell pool. Other CD4 T cell
fractions that were shown to contain T cells with regulatory function are the CD45Rblow
(Powrie et al., 1993) and a E b 7 (CD103)-positive (Lehmann et al., 2002) populations. In
thymus, spleen and LN of CD4-Cre/Ikk2FL/D mice very few CD4+CD25+ T cells can be
found (Figure 25C and E and Table 9). This does not reflect the inability of Ikk2D/D T
cells to express CD25, since these cells upregulate CD25 in vitro in response to various
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stimuli, such as antibodies against CD3, CD3 and CD28, PMA/Iono or ConA over a
period of five days as efficiently as WT T cells (data not shown).
Organ
CD4-Cre
Ikk2FL/D or FL/FL Ikk2FL/D or FL/FL
Thymus 1.17 ± 0.26  4.09 ± 0.54
Spleen 3.70 ± 1.06 13.10 ± 3.20
LN 3.38 ± 2.00 11.75 ± 2.12
Table 9. Percentage of CD4+CD25+ T cells of total CD4 T cells in
thymus, spleen and lymph nodes
Average numbers are shown in millions plus/minus standard
deviation (CD4-Cre/Ikk2FL/D or FL/FL: n = 10; Ikk2FL/D or FL/FL: n = 10).
This lack of CD4+CD25+ T cells is paralleled by a similar deficiency in CD45Rblow
cells in CD4-Cre/Ikk2FL/D mice (data not shown), suggesting that these mice have a
severe deficiency in regulatory T cell populations defined by these markers. No
significant difference in a E b 7-expressing T cell numbers was found between CD4-
Cre/Ikk2FL/D and control mice (data not shown). WT CD4+CD25+ T cells in spleen and
LNs are smaller, as assessed by forward scatter, than those in the thymus, possibly
reflecting a maturation process; in contrast peripheral CD4+CD25+ T cells isolated from
CD4-Cre/Ikk2FL/D mice are of the same size as in the thymus, if not larger (Figure
25D). This indicates that the CD4+CD25+ T cells remaining in CD4-Cre/Ikk2FL/D mice
are different from those in control mice. CD4+CD25+ T cells have been reported to
express the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; CD152)
constitutively (Read et al., 2000; Takahashi et al., 2000). CD4+CD25+ T cells in CD4-
Cre/Ikk2FL/D mice express CTLA-4 to the same level as those in control mice and they
also display a normal pattern of CD45Rb-expression (data not shown), suggesting that
they could be regulatory T cells. Analysis of CD44 expression on peripheral CD4 and
CD8 T cells showed that CD4-Cre/Ikk2FL/D mice have a clear deficiency in
CD4+CD44+ memory-type T cell numbers and, to a lesser extent, in CD8+CD44+ cell
numbers (Figure 25F and G). Indeed the reduction of CD4 T cells in CD4-Cre/Ikk2FL/D
mice can largely be accounted for by the absence of subsets that were shown to contain
T cells with regulatory (CD4+CD25+) and memory (CD4+CD44+) functions

Figure 25. Analysis of T cell populations in CD4-Cre/Ikk2FL/D mice
compared to control mice.
(A, B) Bar charts of absolute CD4, CD8 T cell and B cell numbers in Spleen (A)
and LN (B). Black bars represent control (Ikk2FL/D or Ikk2FL/FL; n = 10) and grey
bars represent CD4-Cre/Ikk2FL/D or FL/FL mice (n = 10).
(C) FACS analysis of CD25 expression on CD4 T cells in thymus, spleen and
LNs.
(D) Size of CD4/CD25 T cells indicated by forward scatter. Black histograms
represent control (Ikk2FL/D or Ikk2FL/FL) and grey histograms represent CD4-
Cre/Ikk2FL/D or FL/FL mice.
(E) Proportion of CD25-positive of total CD4 T cells. Black bars represent
control (Ikk2FL/D or  Ikk2FL/FL; n = 10-12) and grey bars represent CD4-
Cre/Ikk2FL/D or FL/FL mice (n = 10-12).
(F) FACS analysis of CD44 expression on CD4 T cells in spleen and LNs.
(G) Proportion of CD44-positive of total CD4 T cells. Black bars represent
control (Ikk2FL/D or Ikk2FL/FL; n = 9) and grey bars represent CD4-Cre/Ikk2FL/D or
FL/FL (n = 9) mice.
Genotypes are as indicated. Cell surface markers are shown as coordinates and
gated cell populations are indicated in brackets. The numbers in the quadrants
refer to the percentage of the respective T cell population of live cells in the





Ikk2FL/D or FL/FL Ikk2FL/D or FL/FL
Spleen CD4/CD44 4.90 ± 0.39 15.92 ± 1.22
CD8/CD44 8.00 ± 2.71 11.42 ± 1.45
LN CD4/CD44 3.94 ± 0.62  7.64 ± 1.40
CD8/CD44 5.02 ± 1.51  7.06 ± 1.16
Table 10. Percentage of CD44+ T cells of total CD4 or CD8 T cells in
spleen and lymph nodes
Average percentages are shown in bold plus/minus standard deviation
(CD4-Cre/Ikk2FL/D or FL/FL: n = 9; Ikk2FL/D or FL/FL: n = 9).
3.5.3 IKK2-deficient T Cells Can Activate NF- B, Proliferate in vitro and Elicit T-
dependent Immune Responses
In order to test to what extent IKK2-deficient T cells can activate NF- k B, I purified
peripheral T cells from CD4-Cre/Ikk2FL/D mice by FACS and activated them in vitro
with TNF, or with antibodies directed against CD3 and/or CD28. Surprisingly, Ikk2D/D
T cells could significantly activate NF-k B in response to these stimuli, only slightly
less than control T cells (Figures 26A and B). Also the NF-k B subunit composition in
TNF- and anti-CD3/CD28-stimulated Ikk2D/D T cells was similar to that in control T
cells (Figure 26C and data not shown). I performed Western blotting to prove that the
Ikk2D/D T cells used in the activation experiments are IKK2-deficient (Figure 26D).
I also found that under certain conditions Ikk2D/D CD4 and CD8 T cells can proliferate
in vitro as efficiently as control T cells in response to a panel of stimuli (Figures 27A -
C). Similarly, there was no difference between WT and Ikk2D/D CD4 and CD8 T cells
in level of activation marker expression, such as CD69, CD62L, CD44 or CD25, after
anti-CD3, anti-CD3/CD28, PMA/Ionomycin or Concanavalin A treatment for 24 h, or
5 days (data not shown). To test the proliferative abilities of IKK2-deficient T cells in a
more physiological context I injected CFSE-labeled T cells into syngeneic C57/BL/6
RAG-/- hosts. Naïve and memory T cells proliferate spontaneously in a lymphopenic
environment. During this homeostasis-driven proliferation naïve T cells gain
phenotypic and functional characteristics of memory T cells (Goldrath, 2002). After 5,
Figure 26. NF- B activation in IKK2-deficient T cells
(A, B) NF-k B EMSA of whole cell lysates of sorted T cells from mice of
indicated genotypes stimulated with TNF (A; 20 ng/ml) or anti-CD3 or anti-
CD3/CD28 antibodies (B; four antibody coated beads per cell) for the indicated
time-periods. Equal amount of nuclear protein was demonstrated by Oct-1
mobility shift.
(C) NF-k B Supershift-analysis of extracts of TNF (20 ng/ml - 20 min)
stimulated T cells
(D) Western Blot analysis on pooled whole cell lysates of T cells stimulated with
TNF (A) or anti-CD3/CD28  antibodies (B) from CD4-Cre/Ikk2FL/D and Ikk2FL/D
mice. Equal amounts of whole cell lysate of each time point were pooled per































































Figure 27 .  IkkD/D T cells can proliferate in vitro as well as WT T cells
T cells were isolated from LN and spleen of CD4-Cre/Ikk2FL/D or FL/FL and control mice,
labelled with CFSE and activated in vitro to proliferate using CD3 or CD3/CD28 coated
beads (one bead per cell), PMA (2 nM)/Iono (1m M) or ConA (1 m g/ml). After 3  and 5 days
cells were harvested, analysed by FACS (A, B) and counted (C, D). This experiment was
repeated twice with similar results. (A, B) Analysis of cell divisions in activated IkkD/D and
control T cell cultures. Histograms represent populations gated on live CD4 (A) or CD8 (B)
cells as a function of CFSE intensity and cell number.  T cell genotype and stimulus are as
indicated next to and above the histograms. The number of cell divisions is indicated by lines
and by numbers above each histogram. The results shown are representative of triplicate
wells. (C, D) Absolute cell numbers in  IkkD/D and control T cell proliferation cultures. Cell
counting was performed using Trypan blue exclusion. Total cell numbers are indicated by
bars (grey part = live cells; black part = dead cells). T cell genotype and stimulus are as
indicated below the bar charts. Error bars represent standard deviations of triplicate samples.
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6 or 10 days the mice were sacrificed, spleens and LNs were removed and proliferation
was assessed by FACS-analysis (Figure 28). After five days, most of the control CD8 T
cells had divided 3 to 5 times, whereas most Ikk2D/D T cells seemed to have undergone
only 2 to 3 divisions (Figure 28A). A similar picture was observed after 6 days, but
after 10 days IKK2-deficient and control T cells showed a similar cell-division profile
(Figure 28A). CD4 T cells expand slower in a lymphopenic environment (Goldrath,
2002). After 6 and 10 days I could clearly observe control CD4 T cells that had
undergone one cell division. In contrast Ikk2D/D CD4 T cells did not divide to any
significant extent at any time (Figure 28B). Moreover, only very few Ikk2D/D CD8 and
CD4 T cells could be recovered at all time points from spleen and LNs, in contrast to
control T cells (Figure 28A and B), indicating that IKK2-deficient T cells cannot
expand efficiently in lymphopenic hosts, probably due to a survival defect. However,
this analysis has to be repeated with more mice to ensure the finding.
To test the function of IKK2-deficient T cells in vivo I immunized CD4-Cre/Ikk2FL/D
and control mice with the T-dependent (TD) antigen NP-CG. B cells depend on T cell
help to elicit a humoral immune response to TD antigens. Determination of Ig isotypes
by ELISA showed that basal levels of immunoglobulin titers were normal in CD4-
Cre/Ikk2FL/D mice, except for a slight reduction in serum concentration of IgE (Figure
29A). IKK2-deficient T cells were able to provide B cell help in the course of an
immune response, since CD4-Cre/Ikk2FL/D mice mounted an efficient NP-specific
immune-response.  This response was delayed, however, since the serum concentration
of NP-specific IgG1, l  and k  in CD4-Cre/Ikk2FL/D mice was lower than in control mice
at day 7 (Figures 29B, D and E). At day 14 to 28 after immunization NP-specific IgG
serum concentrations were comparable between CD4-Cre/Ikk2FL/D and control mice
(Figures 29B – 7E and data not shown).
Figure 28.  Homotypic proliferation in lymphopenic hosts in vivo of IkkD/D
compared to WT T cells
T cells were isolated from LN and spleen of a CD4-Cre/Ikk2FL/D mouse and a
control mouse, labelled with CFSE and injected intravenously into RAG-/-
hosts. After 3, 5 or 10 days RAG-/- hosts were killed and T cells from LN and
spleens cells were prepared and analysed by FACS
(A) Histograms represent populations gated on live CD8 T cells as a function of
CFSE intensity and cell number.  T cell genotype and location are as indicated
above the histograms. The number of cell divisions is indicated by lines and by
numbers above each histogram. Bold numbers in the top left corner of each
histogram indicate the total number of retrieved CD8 T cells from individual
RAG-/- hosts.
(B) Histograms represent populations gated on live CD4 T cells as a function of
CFSE intensity and cell number.  T cell genotype and location are as indicated
above the histograms. The number of cell divisions is indicated by lines and by
numbers above each histogram. Bold numbers in the top left corner of each





4.1. NEMO in NF- B Activation and Embryonic Development
NEMO deficiency resulted in a lethal phenotype and a complete block of NF-k B
activation by proinflammatory stimuli. The latter contrasted, in a side-by-side
comparison, with IKK2 deficiency, which leads to reduced, but still detectable NF-k B
activation under the same conditions, probably because the absence of IKK2 can be
partially compensated by IKK1. It has been shown that LPS predominantly stimulates
IKK2 activity (Fischer et al., 1999); in agreement with this result I find that IKK2
deficiency completely blocked NF-k B activation in response to LPS. Liver
degeneration is the cause of embryonic lethality in mice lacking the RelA/p65 NF-k B
subunit or IKK2 (Beg et al., 1995; Li et al., 1999b; Li et al., 1999c; Tanaka et al.,
1999). A similar phenotype is also observed in NEMO-deficient embryos, but in this
case liver apoptosis seems to occur earlier than in relA-/- or ikk2-/- embryos,
underscoring the essential role of NEMO in the NF-k B activation process. These
results were confirmed by the independent work of two other research groups (Makris
et al., 2000; Rudolph et al., 2000).
4.2. NEMO-deficient Mice as an Animal Model for the Human Disease
Incontinentia Pigmenti
The localization of Nemo on the X chromosome predicts that random X inactivation
will generate a chimerism of NEMO-deficient and NEMO-containing cells in all
tissues of NemoD/WT females. Given the central role of the NF-k B signaling pathway in
the regulation of various cellular responses (Gerondakis et al., 1998; Kanegae et al.,
1998; O'Neill and Kaltschmidt, 1997), the presence of NEMO-deficient cells in the
body could cause defects in multiple tissues. Indeed, recent work has shown that
mutations in the human NEMO gene cause Incontinentia Pigmenti (IP) (Smahi et al.,
2000).
I show here that heterozygous Nemo knockout mice develop a skin phenotype that
closely resembles the cutaneous manifestations observed in IP patients. The skin
abnormalities in these animals seem to occur in stages that correlate to the different
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stages described for IP. A few days after birth numerous inflammatory foci are found in
the epidermis of NemoD/WT mice, showing massive infiltration of granulocytes into the
epidermis, resembling the inflammatory phase I of IP (Landy and Donnai, 1993). At
eight days, granulocyte infiltrates into the epidermis are reduced, suggesting that at this
age features reminiscent of an initial inflammatory episode are declining, as in stage II
of IP (Landy and Donnai, 1993). Histological examination of the skin from NemoD/WT
mice revealed epidermal hyperplasia with thickening of both the suprabasal and the
cornified layer. Electron microscopy showed that in the epidermis of NemoD/WT mice
basal layer keratinocytes are in loose contact forming dilated intercellular spaces. This
defect may be associated with alterations in tonofilaments and loss of desmosomal
structures that were also observed. Presence of dyskeratotic keratinocytes displaying
abnormal tonofilaments, loss of desmosomal contacts, and dilated intercellular spaces
are reported in stage II IP patients (Schamburg-Lever and Lever, 1973).
Hyperpigmentation caused by the presence of increased numbers of melanosome
containing phagocytes in the dermis is the hallmark of IP, occurring at stage III
(Schamburg-Lever and Lever, 1973; Zillikens et al., 1991). A similar phenomenon was
also observed in the NemoD/WT mouse model, at 6 weeks of age. Furthermore, I and
others found that NEMO deficiency results in embryonic lethality in hemizygous males
both in mice and in humans (Rudolph et al., 2000; Smahi et al., 2000). It will be
interesting to see whether aborted male IP embryos also show liver degeneration due to
hepatocyte apoptosis.
A further similarity between IP patients and NemoD/WT mice relates to the
hematopoietic system. The blood leukocytes of IP patients exhibit a completely skewed
pattern of X-inactivation, suggesting that cells expressing the mutated chromosome are
selectively eliminated (Scheuerle, 1998). Strikingly, chimeras generated from Nemo
knockout ES cells did not possess any ES cell-derived lymphocytes. Thus, lymphocytes
lacking NEMO expression either do not develop or are counter-selected.
How can the dominant feature of the disease developing in IP patients and NemoD/WT
mice, namely the skin disorder, be explained? Several reports have suggested that NF-
k B activation is essential for the normal development of the epidermis. A dramatic skin
phenotype is reported in IKK1 knockout mice which die shortly after birth showing a
thickened hyperproliferative epidermis lacking keratinocyte differentiation (Hu et al.,
1999b; Li et al., 1999a; Takeda et al., 1999). However, this was later demonstrated to
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be independent of I- k B kinase activity and of NF- k B (Cao et al., 2001; Hu et al., 2001).
In a different experimental setting, keratinocyte-specific inhibition of NF-k B by
expression of a dominant-negative Ik Ba  transgene under the control of the keratin 14
promoter was applied to study the role of NF-k B in stratified epithelium (Seitz et al.,
1998). These transgenic mice developed epidermal hyperplasia within 4 days after
birth, lacked evidence of normal hair formation, exhibited growth retardation and died
within 5 to 7 days after birth. Based on these results, the authors proposed that
functional loss of NF-k B leads to keratinocyte hyperproliferation. The same group also
showed that NF-k B inhibition results in increased apoptosis of keratinocytes in vivo
(Seitz et al., 2000a; Seitz et al., 2000b). In the skin lesions from NemoD/WT animals I
observed a combination of hyperproliferation and increased cell death. It seems likely
that the affected areas detected on the skin from NemoD/WT mice consist of
keratinocytes that lack NEMO protein because of random X inactivation and therefore
cannot activate NF-k B.  Proliferating cells were detected not only in the basal layer of
these skin patches, but also in the suprabasal layers of the epidermis indicating
abnormal keratinocyte differentiation. Failure to activate NF-k B may cause
hyperproliferation, incomplete differentiation and premature cell death of NEMO-
deficient keratinocytes, resulting in the macroscopic picture of verrucous scaling skin.
Increased apoptosis of NEMO-deficient basal keratinocytes could lead to their
progressive replacement by NEMO expressing keratinocytes and thus to the gradual
clearance of the skin lesions. TNF and other cytokines that may be produced in the
epidermis during the early inflammatory phase could play a role in this process by
directly killing the NEMO-deficient keratinocytes. Experimental evidence showing that
NF- k B inhibition in vitro sensitizes primary keratinocytes to apoptosis induced by TNF
or Fas (Seitz et al., 2000b) further supports this hypothesis. However, although TNF-
induced NF-k B activation is markedly reduced in IKK2-deficient keratinocytes, they
show only mildly increased apoptosis on TNF treatment compared to controls
(Pasparakis et al., 2002a). This shows, that TNF-induced killing of Ikk2-knockout
keratinocytes does not play an important role in the pathogenesis of the inflammatory
skin disease caused by epidermis-specific deletion of IKK2 (Pasparakis et al., 2002a).
It has also been postulated for human IP that invasion of affected skin by normal cells
takes place at the transition from the inflammatory to the verrucuous stage (Wieacker et
al., 1985).  Studies in mice with epidermis-specific deletion of IKK2 (K14-
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Cre/IKK2FL/FL) showed that IKK2 deficiency inhibited NF-k B activation in
keratinocytes, but did not lead to cell-autonomous hyperproliferation or impaired
differentiation. Mice lacking IKK2 specifically in the epidermis develop an
inflammatory response that develops in the skin shortly after birth and leads to their
death at around day 10 after birth (Pasparakis et al., 2002a). Subsequent to upregulation
of cytokines in epidermis and dermis and infiltration by immune cells keratinocytes
start to hyperproliferate and epidermal differentiation patterns are abrogated
(Pasparakis et al., 2002a). Treatment of newborn K14-Cre/IKK2FL/FL mice with
neutralizing antibodies against TNF or crossing these mice onto a TNFR1-/- genetic
background completely rescued the skin-phenotype. K14-Cre/IKK2FL/FL/TNFR1-/- mice
develop normally (Pasparakis et al., 2002a). The skin phenotype is also ameliorated in
NemoD/WT/TNFR1-/- mice, but they still develop lesions and the mortality remains high.
Studies employing K14-Cre/ NemoFL/WT, K14-Cre/NemoFL/Y, K14-
Cre/NemoFL/WT/TNFR1-/- and K14-Cre/ NemoFL/Y/TNFR1-/- mice will reveal whether
this is due to a TNF-independent defect in other organs in NemoD/WT mice or to the
presence of NEMO-proficient and –deficient keratinocytes in the skin of these animals.
These mice will also reveal whether the lack of NEMO has a more severe (and partly
TNF-independent) effect on the epidermis than the lack of IKK2.
At this point it remains unclear why most NemoD/WT females die within the first 10 days
of life. The lethal effect of keratinocyte-specific inhibition of NF-k B activation in
transgenic mice (Seitz et al., 1998) supports the hypothesis that the skin lesions in
NemoD/WT mice interfere with vital skin functions causing death of the animals. This
view is supported by the data from Pasparakis et al., showing that deletion of IKK2
specifically in the epidermis leads to death of all animals before they are two weeks old
(Pasparakis et al., 2002a). Therefore it might depend on the percentage of NEMO-
deficient cells generated by X-chromosome inactivation whether an animal survives or
succumbs to the disease. Indeed, the few NemoD/WT mice that survive after day ten
showed a milder phenotype from the beginning, with only a small area of the skin
covered by the lesions. Early lethality does not seem to be a prominent feature in
female IP patients.
The repair mechanism proposed to heal the skin defect by the replacement of NEMO-
deficient with NEMO-expressing cells may apply also to other tissues. The increased
number of apoptotic cells observed in the fetal liver of NemoD/WT embryos might
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represent NEMO-deficient hepatocytes whose death at this stage presumably “clears”
the liver from NEMO-deficient cells. Whether a similar mechanism operates also in
other tissues could be assessed by the quantitation of the percentage of NEMO-
deficient cells persisting in these tissues at different developmental stages. This would
uncover the importance of NEMO-mediated NF- k B activation for the survival of
individual cell types in vivo in an ideal experimental setting. I tried to approach this
question using mosaic inactivation of Nemo by crossing mice containing a floxed Nemo
allele to the balancer-Cre strain (Betz et al., 1996). Unfortunately deletion with the
balancer-Cre varied a lot from mouse to mouse so that it was difficult to reach clear
conclusions from the results obtained in this study. Additionally I crossed the
NemoD/WT with mice carrying a EGFP-transgene on the X-Chromosome (Hadjantonakis
et al., 1998). In the resulting NemoD/EGFP offspring I planned to assess presence or
absence of cells that have inactivated the X-chromosome bearing the deleted nemo
allele by quantitating the proportion of GFP-expressing cells in various cell-types and
tissues. Unfortunately in adult mice the EGFP-transgene was object to epigenetic
silencing and therefore no conclusive results could be obtained from these experiments.
In the future I will readdress these issues by using improved genetic tools, such as
HPRT(X-linked)-GFP-knockin mice.
The striking similarities between the skin phenotype we observe in the NemoD/WT mice
and the skin lesions described in IP, which is caused by mutations in the human NEMO
gene, indicate that these mice constitute a model for human IP. Further analysis of
these mice should increase our understanding of the molecular mechanisms involved in
the pathogenesis of this disease. Cell-type-specific and/or inducible inactivation of the
loxP-flanked Nemo gene, which we have introduced into the mouse germline as part of
our targeting strategy, will not only help in this context in the future, but also allow us
to study the role of the NF-k B signaling pathway in other cellular compartments in the
mouse.
4.3 The ikk2 KFL Allele Produces a Kinase-dead Protein
Comparison of NF-k B activation in response to proinflammatory signals in Ikk2 KD/D
and IKK2-deficient MEFs showed a similar impairment measured by EMSA or Ik Ba
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degradation. However, measuring induction of NF-k B-dependent gene products in
response to inflammatory signals, such as TNF induced death and IL-6 production,
Ikk2 KD/D cells showed lower NF-k B activity than IKK2 deficient cells. These results
suggest that the expression of IKK2D K, even at the low levels observed, contributes to
a stronger reduction of NF-k B activity than IKK2-deficiency, presumably by a
dominant-negative effect.
At this stage I can only speculate how this dominant-negative effect comes about. In
wild-type cells the most prevalent IKK dimer is the IKK1/2 heterodimer. Therefore it
seems likely that in Ikk2 KD/D cells IKK2D K is preferentially integrated into the
complex, even though there is a vast excess of IKK1 compared to IKK2D K. In addition
the presence of one IKK1/IKK2D K dimer in the 700 – 900 kD IKK complex could
disrupt the activation process, which depends on cross-phosphorylation between the
kinases (Delhase et al., 1999). After liberation from Ik B NF- k B can bind to DNA, but
transcriptional activation is additionally regulated by further modifications of the Rel
proteins, such as phosphorylation and acetylation (Ghosh and Karin, 2002). Both IKKs
are implicated in this process (Sizemore et al., 2002). IKK complexes consisting of
IKK1 only could be more efficient in initiating the events leading to phosphorylation of
Rel proteins than IKK complexes also containing the kinase-inactive IKK2D K.
4.4 IKK-mediated Activation of NF- B is Essential for Mature B Cell
Maintenance
I investigated the role of IKK-induced NF-k B activity in B cells by conditional
inactivation of IKK2 and NEMO. B cell specificity was achieved by crossing mice
carrying conditional NEMO and IKK2 alleles (Ikk2FL/D, Ikk2 KFL/D and NemoFL/Y) to
CD19-Cre mice. All three mutations similarly lead to a strong reduction of B cell
numbers in mutant mouse strains. CD19-Cre/Ikk2FL/D, -Ikk2 KFL/D or -NemoFL/Y mice
have 3-4 fold reduced B cells in the spleen and at least two-fold reduced numbers in
recirculating bone marrow B cells, lymph node B cells and peritoneal cavity B1 and B2
cells. Southern blot analysis of sorted B cell populations revealed that whereas deletion
efficiency in IgM- bone marrow B cells is as high as reported for CD19-Cre mice and
comparable to deletion observed in CD19-Cre/Ikk2FL/WT mice, IgM+ bone marrow B
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cells are already counterselected, most likely reflecting counterselection against
recirculating B cells. In the transition from IM to FO B cells the percentage of B cells
with deleted alleles is reduced, indicating that mature B cells lacking IKK activity are
counter-selected. In the case of CD19-Cre/Ikk2FL/D and -Ikk2 KFL/D mice over 90% of
the IM B cells have deleted the floxed allele, whereas in FO cells, which presumably
originate from the immature transitional cells, the proportion of cells carrying the
deletion ranges from 40 to 70 %, clearly demonstrating counterselection of IkkD/D- and
Ikk2 KD/D B cells. In CD19-Cre/NemoFL/Y mice, NemoD/Y IM B cells are already
counter-selected, as evidenced by Southern blot and cell counting. The fact that
deletion of NEMO, in contrast to the deletion of IKK2, seems to lead to counter-
selection of cells already within the immature B cell compartment may be explained in
two ways. One explanation is that in the absence of IKK2 some IKK-induced NF-k B
activation can still occur while loss of NEMO completely blocks IKK activity. Thus, in
CD19-Cre/Ikk2FL/D mice low levels of remaining NF-k B activity could be sufficient to
sustain development of B cells to the IM stage. In the CD19-Cre/NemoFL/Y mice the
complete absence of NF- k B activity may lead to the loss of IM B cells. Additionally or
alternatively different turnover rates of IKK2 and NEMO mRNA and protein could
play a role. The relatively long half-life of IKK2(Fischer et al., 1999) might ensure that
most B lineage cells of CD19-Cre/Ikk2FL/D mice develop into FO B cells before they
are devoid of this protein. The half-life of NEMO could be shorter than that of IKK2,
leading to a rapid depletion of NEMO protein from IM B cells that have deleted the
nemoFL allele, resulting in the loss of cells at this stage. The fact that CD19-
Cre/Ikk2 KFL/D mice display an intermediate phenotype with some loss of deleted IM
B cells, as demonstrated by the reduction of the absolute cell numbers of IM B cells in
these mice, is compatible with both hypotheses, since the production of IKK2D K may
lead both to the earlier loss and to more complete inhibition of IKK activity in
comparison to the CD19-Cre/Ikk2FL/D mice.
The picture seen in MZ B cells differs from that seen in FO B cells. The remaining MZ
B cells of the IKK-conditional mutant mice crossed to CD19-Cre mice are nearly
completely devoid of the deleted genotype, clearly demonstrating that Ikk2D/D-,
Ikk2 KD/D and NemoD/Y MZ B cells cannot be generated and/or persist. Recent
evidence suggests that MZ B cells represent a self-renewing separate subset of B cells
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(Carvalho et al., 2001; Hao and Rajewsky, 2001). In this case cells of the deleted
genotype would disappear early during the generation of this lineage and a subset of
cells that have lost their ability to delete would be sustained by self-renewal. Another
view is that MZ B cells are a highly antigen-selected population of B cells (Cariappa et
al., 2000; Martin and Kearney, 2000). During this selection process all B cells able to
undergo Cre-mediated deletion should have deleted the loxP-flanked gene and
subsequently disappeared. Thus the virtual absence of MZ B cells with a deleted
genotype in IKK conditional-CD19Cre mice could be due to the fact that the MZ B cell
compartment is not constantly refilled with B cells that recently acquired the deleted
genotype as is the follicular compartment. Alternatively, the absence of MZ B cells
with deleted nemo or ikk2 alleles could mean that MZ B cells are more dependent on
IKK-induced NF- k B activity then other B cell populations. This explanation, which
does not exclude the former, is supported by the specific loss of MZ B cells in p50
deficient mice (Cariappa et al., 2000).
Mature splenic B cells do not proliferate much (Forster et al., 1989; Fulcher and
Basten, 1997; Hao and Rajewsky, 2001), so that in a BrdU incorporation experiment
over the period of one week most of the BrdU-positive B cells in the spleen represent
IM B cells from the BM (Forster et al., 1989). Roughly twice as many CD19-
Cre/NemoFL/Y splenic B cells stain positive for BrdU after one week of BrdU
administration compared to control B cells. This data are consistent with a BrdU-based
B cell turnover analysis in CD19-Cre/Ikk2 KFL/D mice (Pasparakis et al., 2002b). This
means that recently generated B cells constitute a larger fraction of total splenic B cells
in mutant compared to control mice despite the reduction in B cell numbers in mutant
mice. Thus CD19-Cre/Ikk2 KFL/D mice contain a higher percentage of short-lived
splenic B cells than do wild-type mice. These short-lived B cells should be cells that
carry two deleted alleles and are on their way to lose their ability to signal through the
IKK complex and subsequently die.  When B cell influx from the bone marrow is
blocked for one month by interfering with IL-7R signaling using injections of anti-IL-
7R antibodies, Ikk2 KD/D B cells completely disappear from the spleens of these mice.
The fact that only Ikk2 KFL/D B cells remain in these CD19-Cre/Ikk2 KFL/D mice
shows that there must be a strong selection for cells in which Cre is either absent or
cannot function. FO B cells were shown to have an average calculated half-life of 134
days in the absence of replenishment of the splenic B cell pool from the BM (Hao and
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Rajewsky, 2001). Since all of the Ikk2 KD/D FO B cells disappear after one month this
clearly demonstrates that IKK2 signaling is essential for the maintenance of mature B
cells. We therefore conclude that mature B cells need IKK-mediated survival signals.
Based on our experimental findings we envisage the following scenario: Deletion of the
conditional alleles in mice containing the CD19-Cre transgene is initiated in the bone
marrow and continues throughout the later stages of B cell development. B cells that
underwent Cre-mediated recombination initially retain sufficient amounts of IKK2 or
NEMO protein to allow development into IM B cells and some of these cells progress
further into the mature B cells compartments. B cells that escape Cre-mediated deletion
develop normally into mature B cell subsets. Thus, the follicular B cell compartment of
these mice consists of a mixture of cells that have already deleted and cells that retain
loxP-flanked alleles. The fact that blockade of B cell development in the bone marrow
for four weeks leads to the disappearance of all B cells that have deleted the ikk2 K
floxed alleles from the spleen demonstrates that mature B cells can not survive without
IKK2 activity.
It has been speculated that constitutive activation of NF-k B by signaling through the
BCR is essential for B cell survival (Bendall et al., 1999; Petro and Khan, 2001). In
agreement with this idea B cells die by apoptosis upon inducible deletion of the B cell
receptor (BCR) (Lam et al., 1997). However, it was shown recently that while deletion
of Bcl10 in mice selectively abolishes NF-k B activation by the antigen receptor in B
cells, Bcl10-/- mice show normal B cell development. This argues against the
possibility that NF-k B activation originating from the BCR is needed for B cell
survival (Ruland et al., 2001). Therefore mature peripheral B cells seem to depend on
NF- k B activating signals other than BCR crosslinking, even though a role for the BCR
in this process cannot be excluded with certainty. BAFF is a TNF-family protein that is
expressed mainly on myeloid cells (Hu et al., 1999a; Moore et al., 1999; Schneider et
al., 1999); BAFF-deficient mice revealed a block in B cell development a the T1 to T2
transitional checkpoint, leading to loss of follicular and marginal zone B lymphocytes
(Schiemann et al., 2001). It has been shown that BAFF induces processing of p100 and
nuclear translocation of p52 and RelB via the BAFFR and NIK (Claudio et al., 2002;
Mackall et al., 1996). This process, however, is independent of NEMO (Claudio et al.,
2002) and most likely mediated by IKK1. Since IKK1-deficient B cells develop, albeit
in reduced numbers, BAFF must elicit additional survival signals in B cells apart from
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p100 processing. Ligation of all three receptors for BAFF (BAFFR, BCMA, TACI)
(Mackay et al., 2002) induced phosphorylation of Ik Ba  (Kayagaki et al., 2002) and
treatment with BAFF was shown to induce p50/RelB complexes (Do et al., 2000).
Therefore one potential survival signal initiated by BAFF could be activation of NF-k B
through degradation of Ik B via IKK2 and NEMO. Of course also other receptors,
maybe several receptors acting in concert, could initiate the IKK2- and NEMO
mediated response to keep B cells alive.
4.5 The Role of NEMO and IKK2 in Mature T Cell Development
Activation of NF- k B through degradation of I k Bs is mediated by the IKK complex and
activation of p52/RelB through processing of p100 depends largely on IKK1. Adoptive
transfer experiments, published while this work was in progress, revealed that IKK1 is
dispensable for T cell development (Kaisho et al., 2001; Senftleben et al., 2001a). Also
IKK2 has no essential role in the generation of T cells, but is important for protecting
thymocytes against TNF-induced apoptosis (Senftleben et al., 2001b). These data
indicate that either IKK1 and 2 can compensate for each other or that T cell
development occurs independently of the IKK. On the other hand, inhibition of NF-k B
activation through T cell specific transgenic expression of repressors of NF-k B resulted
in reduced peripheral T cell populations and CD8-SP thymocytes to varying degrees
(Attar et al., 1998; Boothby et al., 1997; Esslinger et al., 1997; Ferreira et al., 1999;
Hettmann et al., 1999). This shows that NF- k B is required for maintenance of normal T
cell numbers, especially CD8 T cells; it also shows, however, that inhibition of NF-k B
was not complete or that T cells can be generated in the absence of NF-k B activity.
Even though these studies yielded important information about the role of NF-k B in T
cells no clear conclusions could be drawn concerning the dependence of T cell
development on activation of NF- k B. Therefore I chose to analyze the function of the
IKK complex in T cells of the adult mouse employing conditional gene targeting.
Absence of NEMO leads to disruption of the IKK complex and blocks IKK-mediated
activation of NF- k B. T cell-specific ablation of NEMO was achieved by crossing mice
a conditional nemo allele (NemoFL/Y) to CD4-Cre mice. The complete disruption of the
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IKK complex in T cells of CD4-Cre/NemoFLY/ mice was compared to the deletion of
IKK2 in CD4-Cre/Ikk2FL/D mice.
In mice containing the CD4 transgene deletion of loxP-flanked alleles in T cells is
consistently complete from the DP stage on (Lee et al., 2001; Wolfer et al., 2001). The
data obtained from CD4-Cre/NemoFL/Y mice unambiguously demonstrate that T cells in
which the IKK has been disrupted through absence of NEMO are not viable. At this
stage I cannot determine exactly when absence of IKK-mediated NF-k B activation
leads to the loss of deficient T cells. In the thymus of CD4-Cre/NemoFL/Y mice CD8-SP
thymocytes are reduced compared to control mice, mainly because of a lack of more
mature HSA low/- CD8-SP cells. In these mice CD4-SP thymocytes are found in nearly
normal proportions, even though there is also a loss of CD4-SP/HSAlow/- cells. These
findings suggest that T cells with deleted nemo alleles start disappearing as they mature
in the thymus. The presence of a small population of splenic CD4 cells with deleted
nemo alleles indicates that some CD4 cells may survive for a short time after they exit
the thymus and populate the periphery. Although different interpretations could be
envisaged, I favor the hypothesis that NemoD/Y T cells die as soon as they lose all their
reserves of NEMO mRNA and protein. Deletion at the DP thymocyte stage creates
NemoD/Y cells that still contain sufficient levels of wild-type NEMO mRNA and protein
to survive and get positively selected to become CD4 and CD8 single positive cells.
The residual amount of remaining NEMO protein in DP and CD4-SP thymocytes from
CD4-Cre/NemoFL/Y showing more than 95% deletion at the DNA level further supports
this hypothesis. As NemoD/Y thymocytes mature, they slowly lose their mRNA and
protein reserves through turnover and become deficient in IKK signaling. When IKK
activity falls below a certain threshold the cells cannot be maintained anymore and die.
This leads to the very small number of peripheral T cells in CD4-Cre/NemoFL/Y mice
that still contain loxP-flanked alleles, which means that they have escaped Cre-
mediated recombination. A minor fraction of NemoD/Y CD4 peripheral T cells can be
detected. These are presumably cells that deleted Nemo late in development and still
retain sufficient endogenous NEMO protein to stay alive until the protein is lost
completely. Nearly all peripheral T cells in CD4-Cre/NemoFL/Y mice are CD44+. This
indicates that the few T cells that escaped deletion underwent homeostatic proliferation
to expand within this lymphopenic environment. During homeostatic expansion T cells
acquire phenotype and functions of memory T cells (Goldrath, 2002).
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T cells that lack IKK2, on the contrary, persist in the periphery, albeit in reduced
numbers. Spleen and LNs of CD4-Cre/Ikk2FL/D mice contain less than 50 % CD8 and
around 80 % CD4 T cells of control mice in absolute numbers. More detailed analyses
revealed that the lack of CD4 T cells is mostly due to T cells defined by CD25, CD44
and/or CD45Rblow surface expression. CD4 T cell subsets defined by these markers
have been shown to contain suppressive/regulatory (CD25+, CD45Rblow) and memory
(CD44+, CD45Rb low) functions. The reduction in CD4+CD25+ T cells can be observed
already in the thymus, where regulatory T cells are thought to be generated (Read and
Powrie, 2001; Shevach, 2001). I found that in control mice CD4+CD25+ T cells in
spleen and LNs are smaller than those in the thymus, whereas in CD4-Cre/Ikk2FL/D
mice the size remains constant. Since more immature cells are bigger this could
indicate that peripheral CD4+CD25+ T cells in CD4-Cre/Ikk2FL/D mice are cell that
emigrated recently from the thymus and disappear before they develop into smaller,
more mature T cells. However, so far I could not detect additional differences between
CD4+CD25+ T from  CD4-Cre/Ikk2FL/D and those from control mice: the remaining
peripheral CD4+CD25+ T cells in CD4-Cre/Ikk2FL/D mice express constitutive CTLA-4
to the same extent as control CD4+CD25+ T cells and are slightly lower in CD4 as has
been published for regulatory T cells (Read et al., 2000; Takahashi et al., 2000). I
presently do not know whether the defect in CD4+CD25+, CD4+CD45Rblow and
CD4+CD44+ T cells in CD4-Cre/Ikk2FL/D mice reflects a true deficiency in regulatory
and/or memory function.
IKK2-/-TNFR1-/- double deficient thymocytes were reported to have a complete defect
in IKK activation and NF-k B DNA binding and reduced [3H]thymidine uptake in
response to plate-bound anti-CD3 treatment and to a lesser extent to PMA/Ionomycin
or Concanavalin A treatment (Senftleben et al., 2001b). I used EMSA to measure NF-
k B activation in FACS-purified Ikk2D/D and control peripheral T cells upon stimulation
with TNF, anti-CD3 or anti-CD3/CD28. The response of Ikk2D/D T cells to these stimuli
was somewhat weaker than that of control T cells, however IKK2-deficient T cells
could clearly activate NF-k B to a significant extent. The composition of the induced
NF- k B complexes is similar in IKK2-deficient and control T cells. It is well
documented that in MEFs in the absence of IKK2 residual NF-k B activation occurs in
response to proinflammatory stimuli (Li et al., 2000; Li et al., 1999b; Schmidt-Supprian
et al., 2000; Tanaka et al., 1999). It seems that T cells can compensate better for the
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loss of this protein. How this compensation is effected is difficult to predict. It seems
possible that in the absence of IKK2 other kinases or co-activator proteins, present in T
cells but not or in much lower levels in MEFs, associate with IKK1 and allow for NF-
k B activation. One candidate could be IKKe  (also known as IKKi), a kinase that was
shown to phosphorylate Ik B at one serine residue in vitro (Peters et al., 2000). Another
possibility is that in T cells upstream activators of the IKK complex are expressed that
can activate IKK1 homodimers better than those expressed in MEFs. At this point we
cannot explain the obvious contradiction with the complete absence of NF-k B
activation in IKK2-/-TNFR1-/- double deficient thymocytes. However, the speculations
about the differences between MEFs and T cells could also apply to thymocytes and T
cells. In light of the finding that NEMO-deficient T cells do not exist, it seems
reasonable to argue that the ability of IKK2-deficient T cells to activate NF-k B allows
their generation and persistence. Analysis of [3H]thymidine incorporation in response
to plate-bound anti-CD3 treatment revealed a mild defect in IKK2-deficient compared
to control T cells. Using different experimental settings we observed that IKK2-
deficient T cells could be induced to proliferate in vitro as well as control T cells in
response to a whole variety of stimuli, demonstrating that these cells have no intrinsic
defect impairing cell division. Similarly Ikk2-/- T cells can be induced to efficiently
upregulate activation markers with normal kinetics. I acknowledge that these assays do
not exclude potential defects of IKK2-deficient T cells to physiological responses in
vivo. Nevertheless these data show that T cells without IKK2 can execute programs
necessary for cellular functions such as proliferation and upregulation of activation
markers, which are generally believed to depend to some extent on NF-k B activation.
To test the function of IKK2-deficient T cells in vivo I immunized CD4-Cre/Ikk2FL/D
and control mice with the T-dependent antigen NP-CG. Measurement of NP-specific
immunoglobulin concentrations in the serum during the time course of the immune
response revealed that CD4-Cre/Ikk2FL/D mice were able to mount an efficient, albeit
delayed, anti-NP antibody response. This experiment shows that IKK2-deficient T cells
are functional participants in the immune system of the mouse. Although it seems
unlikely, I cannot formally exclude the rapid expansion and subsequent participation in
the immune response of a minute fraction of T cells that escaped Cre-mediated deletion
in CD4-Cre/Ikk2FL/D mice.
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In agreement with published data I show here that IKK2 is not needed for the
development of mature T cells. IKK2-deficient T cells can activate NF-k B, proliferate,
upregulate activation markers and participate in immune responses. It is interesting to
note, however, that IKK2-deficiency leads to a reduction in peripheral T cell numbers,
especially CD8 T cells. Initial data also indicate that IKK2 is essential for the
generation and/or persistence of CD4 T cell subsets that contain T cells with regulatory
or memory functions, defined by co-expression of CD25 or CD44.
In addition to deletion of IKK2 I analyzed the cell-autonomous role of the IKK
complex in T cells through its disruption by deletion of NEMO. My results clearly
show that IKK-mediated activation of NF-k B is essential for the generation of mature T
cells from single-positive thymocytes. Additionally my data suggest that IKK-signaling




I generated a mouse strain harboring a conditional allele (NemoFL) of the X-linked gene
encoding NF- k B essential modulator (NEMO), in order to analyze the function of the
activation of the NF-k B transcription factor family via the Ik B-Kinase complex (IKK)
in the immune system of the mouse.
Biochemical studies using NEMO-deficient murine embryonic fibroblasts (MEFs)
showed that NEMO is indispensable for NF- k B activation. Hemizygous male NEMO
knockout mice die at embryonic day 11.5 displaying massive destruction of the liver.
Heterozygous NEMO knockout (NemoD/WT) female mice develop a progressive
inflammatory skin disease, become runted and growth-retarded and most die six to ten
days after birth. Animals that survive beyond this period of time gradually recover.
Detailed analysis of the histopathology of these mice revealed that an inflammatory
response in the skin of NemoD/WT mice soon after birth leads to hyperproliferation and
increased apoptosis of keratinocytes. Due to random X-inactivation NemoD/WT mice are
mosaic animals, During the inflammatory response the skin is presumably cleared of
keratinocytes unable to express NEMO. It seems that only mice in which initially the
majority of cell have inactivated the X-chromosome harboring the nemoD-allele can
survive this period and recover. Male embryonic lethality and transient inflammatory
skin lesions are characteristic of the human hereditary genodermatosis Incontinentia
Pigmenti, which is caused by mutations in the human NEMO gene. The striking
similarities between the pathology in NEMO-deficient mice and human IP suggest that
the Nemo-knockout mice represent a mouse model for this disease.
The role of the IKK and NF-k B in B and T lymphocytes was investigated by cell-type
specific deletion of Nemo employing CD19-Cre (B cell-specific) and CD4-Cre (T cell
specific) transgenic mouse strains. CD19-Cre/NemoFL and CD4-Cre/NemoFL mice were
compared in a side-by-side analysis to two mutant mouse strains, carrying either a
conditional IKK2 allele (ikk2FL) or a conditional IKK2D K allele ( ikk2 KFL), crossed to
the same Cre-transgenic mice. In Ikk2 KD/D cells IKK2 should be replaced by a kinase-
inactive version of IKK2, IKK2D K. Biochemical analysis of Ikk2 KD/D MEFs revealed
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that the Ikk2 KD-mutation leads to a more pronounced defect in transcription of pro-
inflammatory NF-k B target genes than a mere lack of IKK2.
Analysis of the CD19-Cre/IKK conditional mutants showed that the maintenance of
mature B cells critically depends on signals mediated by IKK2 and NEMO. Disruption
of the IKK2-signaling pathway leads to loss of mature B cells. Deletion of NEMO or
IKK2-activity in T cells mediated by the CD4-Cre transgene yielded a different picture:
Peripheral T cells lacking NEMO cannot be generated and/or persist, whereas IKK2-
deficient T cells are generated, although in reduced numbers. CD4-Cre/IKK2FL mice
have around half the number of CD8 T cells, a profound deficit in the CD4+/CD25+
regulatory T cell population and a reduction in CD44+ memory-type T cells.  Analysis
of IKK2-deficient T cells showed that they can activate NF-k B to a considerable




Ziel dieser Arbeit war es, die Funktion der Aktivierung der Transkriptionsfaktor-
Familie NF- k B durch den I k B-Kinase Komplex (IKK) im Immunsystem der Maus zu
untersuchen. Zu diesem Zweck wurde ein Mausstamm erzeugt, der ein konditionales
Allel (NemoFL) des sich auf dem X-Chromosom befindenden Nemo (NF- k B essential
modulator) Gens enthält.
Zunächst wurde die Rolle von NEMO in der Entwicklung der Maus anhand von
NEMO-defizienten Mäusen (NEMO-knockout Mäuse) untersucht. Biochemische
Analysen an NEMO-defizienten embryonalen Fibroblasten (MEFs) zeigten, dass ohne
NEMO keine Aktivierung von NF-k B möglich ist. Hemizygote männliche NEMO-
knockout Mäuse sterben an Tag 11.5 der Embryonalentwicklung und weisen eine
weitgehende Degeneration der Leber auf. Heterozygote weibliche NEMO-knockout
Mäuse (NemoD/WT) entwickeln eine progressive Hautkrankheit mit Anzeichen von
lokalen Entzündungsreaktionen. Sie bleiben zunehmend im Wachstum zurück und die
meisten sterben sechs bis zehn Tage nach Geburt. Tiere, die diese Phase überleben,
erholen sich nach einigen Wochen vollständig. Anhand von detallierten
histopathologischen Untersuchungen dieser Mäuse liessen sich einige Tage nach der
Geburt in der Haut von NemoD/WT Mäusen Anzeichen einer Entzündungsreaktion und
hyperproliferierende und absterbende Keratinozyten nachweisen. Durch X-
Inaktivierung werden NemoD/WT Mäuse genetische Mosaike. Während der
Entzündungsreaktion werden vermutlich in der Haut dieser Tiere die NEMO-
defizienten Keratinozyten durch NEMO-ausprägende Keratinozyten ersetzt. Es scheint
so, dass nur Mäuse, in denen während der X-Inaktivierung hauptsächlich das nemoD-
Allel inaktiviert wurde, überleben und sich erholen können. Embryonale Lethalität und
eine progressive Hauterkrankung sind charakteristisch für die menschliche
Erbkrankheit Incontinentia Pigmenti (IP); in 80 % der IP-Patienten wurden Mutationen
im humanen NEMO Gen gefunden. Die starke Ähnlichkeit des Krankheitsverlaufes in
NEMO-defizienten Mäusen mit Incontinentia Pigmenti zeigt, dass diese Mäuse ein
Tiermodell für die menschliche Erbkrankheit Incontinentia Pigmenti (IP) darstellen.
Die Rolle des IKK Komplexes und NF-k B in Lymphozyten wurde in Mäusen
analysiert, denen NEMO ausschliesslich in B oder T Zellen fehlt. Hierzu wurden
NemoFL Mäuse mit CD19-Cre (B Zellen) oder mit CD4-Cre (T Zellen) transgenen
Mäusen verkreuzt. Der zelltyp-spezifische Verlust von NEMO wurde mit dem Verlust
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von IKK2 und dem Austausch von IKK2 durch eine Kinase-inaktive Variante,
IKK2 D K, verglichen. Biochemische Analysen zeigten, dass der Ersatz von IKK2 durch
die inaktive Mutante IKK2D  einen stärkeren Effekt auf die Transkription von NF-k B-
abhängigen inflammatorischen Genen hat, als das Fehlen von IKK2. Die Analyse der
CD19-Cre/IKK-konditionalen Mausmutanten zeigte, dass reife B Zellen zum
Überleben auf IKK2/NEMO-vermittelte Signale angewiesen sind.
Die Deletion von NEMO oder IKK2 in T Zellen anhand des CD4-Cre Transgens
zeitigte ein anderes Bild: Periphere NEMO-defiziente T Zellen können nicht erzeugt
oder nicht erhalten werden, während IKK2-defiziente T Zellen sich entwickeln können,
wenn auch in verminderter Anzahl. CD4-Cre/IKK2FL Mäuse haben ungefähr die Hälfte
an CD8 T Zellen verglichen mit Kontrollmäusen. Zudem können sich IKK2-defiziente
T Zellen nur vermindert zu CD4+CD25+ oder CD4+CD44+ T Zellen entwickeln, oder als
solche überleben. Dies zeigt, dass IKK2-vermittelte Signale essentiell für die
Erzeugung und/oder Erhaltung bestimmter T Zell Untergruppen sind. Weitergehende
Analysen ergaben, dass T Zellen ohne IKK2 NF-k B aktivieren, Aktivierungsmarker




In dieser Arbeit wurde die Rolle der NF-k B Aktivierung durch den Ik B-
Kinase Komplex in vivo untersucht. Die Erzeugung und Untersuchung von
NEMO-defizienten Mäusen ergab, dass diese ein Tiermodell für die
menschliche Erbkrankheit Incontinentia Pigmenti darstellen. Die Rolle des
den Ik B-Kinase Komplexes in B und T Lymphozyten wurde mit Hilfe von
drei verschiedenen konditionalen Mausstämmen untersucht. Genetische
Manipulationen in diesen Mäusen führt entweder zu Fehlen von NEMO
oder IKK2, oder zum Austausch von IKK2 durch ein IKK2-Protein, das
keine Kinase-Aktivität besitzt. In B Zellen sind IKK2-vermittelte Signale
überlebensnotwendig. In T Zellen dagegen führt die IKK2-Defizienz zur
Reduktion bestimmter T Zell Untergruppen, während das Fehlen von
NEMO und damit von NF-k B Aktivierung durch den IKK Komplex nicht
mit der Erzeugung und/oder Erhaltung von reifen T Zellen vereinbar ist.
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